https://trial.medpath.com/news/dod-awards-11m-for-novel-ulcerative-colitis-trial-combining-biologic-with-plant-based-nutraceutical 2026-03-18T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dod-awards-11m-for-novel-ulcerative-colitis-trial-combining-biologic-with-plant-based-nutraceutical 2026-03-18T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/new-england-biolabs-and-touchlight-launch-cell-free-dna-synthesis-kit-to-accelerate-gene-therapy-development 2026-03-18T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-england-biolabs-and-touchlight-launch-cell-free-dna-synthesis-kit-to-accelerate-gene-therapy-development 2026-03-18T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/crossbow-therapeutics-secures-77-million-series-b-to-advance-tcr-mimetic-cancer-immunotherapies 2026-03-18T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crossbow-therapeutics-secures-77-million-series-b-to-advance-tcr-mimetic-cancer-immunotherapies 2026-03-18T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/jenavalve-s-trilogy-system-becomes-first-fda-approved-tavr-device-for-severe-aortic-regurgitation 2026-03-18T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jenavalve-s-trilogy-system-becomes-first-fda-approved-tavr-device-for-severe-aortic-regurgitation 2026-03-18T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/first-validated-biomarker-transforms-hormone-therapy-decisions-in-recurrent-prostate-cancer 2026-03-18T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-validated-biomarker-transforms-hormone-therapy-decisions-in-recurrent-prostate-cancer 2026-03-18T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/atrogi-doses-first-patients-in-phase-1-trial-of-exercise-mimicking-drug-atr-258 2026-03-18T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrogi-doses-first-patients-in-phase-1-trial-of-exercise-mimicking-drug-atr-258 2026-03-18T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/triplet-therapy-doubles-survival-in-her2-positive-breast-cancer-patients-with-leptomeningeal-metastasis 2026-03-18T17:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triplet-therapy-doubles-survival-in-her2-positive-breast-cancer-patients-with-leptomeningeal-metastasis 2026-03-18T17:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-partners-with-university-at-buffalo-to-develop-novel-sjogren-s-syndrome-biomarkers 2026-03-18T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-partners-with-university-at-buffalo-to-develop-novel-sjogren-s-syndrome-biomarkers 2026-03-18T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/excalipoint-therapeutics-secures-68-7-million-in-seed-funding-to-advance-next-generation-t-cell-engager-pipeline 2026-03-18T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excalipoint-therapeutics-secures-68-7-million-in-seed-funding-to-advance-next-generation-t-cell-engager-pipeline 2026-03-18T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/merit-medical-launches-resilience-tts-esophageal-stent-for-cancer-related-strictures-and-fistulas 2026-03-18T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merit-medical-launches-resilience-tts-esophageal-stent-for-cancer-related-strictures-and-fistulas 2026-03-18T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/eco-innovation-group-acquires-kepler-gtl-s-patent-portfolio-for-sustainable-aviation-fuel-production 2026-03-18T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eco-innovation-group-acquires-kepler-gtl-s-patent-portfolio-for-sustainable-aviation-fuel-production 2026-03-18T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/duke-researchers-develop-nasal-swab-test-for-early-alzheimer-s-detection 2026-03-18T13:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-researchers-develop-nasal-swab-test-for-early-alzheimer-s-detection 2026-03-18T13:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-commits-180m-for-kali-s-novel-trispecific-antibody-in-autoimmune-disease-partnership 2026-03-18T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-commits-180m-for-kali-s-novel-trispecific-antibody-in-autoimmune-disease-partnership 2026-03-18T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotheryx-advances-btx-9341-cdk4-6-degrader-into-dose-expansion-phase-for-hr-her2-breast-cancer 2026-03-18T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotheryx-advances-btx-9341-cdk4-6-degrader-into-dose-expansion-phase-for-hr-her2-breast-cancer 2026-03-18T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-non-tobacco-flavored-e-cigarettes-with-advanced-age-gating-technology 2026-03-18T09:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-first-non-tobacco-flavored-e-cigarettes-with-advanced-age-gating-technology 2026-03-18T09:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-approves-first-enterovirus-a71-vaccine-as-mvc-and-substipharm-target-southeast-asian-expansion 2026-03-18T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-approves-first-enterovirus-a71-vaccine-as-mvc-and-substipharm-target-southeast-asian-expansion 2026-03-18T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-sheffield-receives-ps1m-grant-to-develop-smart-gel-drug-delivery-system-for-glioblastoma 2026-03-18T05:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-sheffield-receives-ps1m-grant-to-develop-smart-gel-drug-delivery-system-for-glioblastoma 2026-03-18T05:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-receives-israeli-regulatory-approval-for-phase-2-3-trial-of-kras-targeting-rnai-therapy-sil204 2026-03-18T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silexion-therapeutics-receives-israeli-regulatory-approval-for-phase-2-3-trial-of-kras-targeting-rnai-therapy-sil204 2026-03-18T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/akamis-bio-s-ng-350a-shows-50-response-rate-in-locally-advanced-rectal-cancer-phase-1b-trial 2026-03-18T01:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akamis-bio-s-ng-350a-shows-50-response-rate-in-locally-advanced-rectal-cancer-phase-1b-trial 2026-03-18T01:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-ends-flovent-monopoly-after-senate-investigation-reveals-367-million-medicaid-rebate-avoidance 2026-03-18T01:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-ends-flovent-monopoly-after-senate-investigation-reveals-367-million-medicaid-rebate-avoidance 2026-03-18T01:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-advances-novel-ras-targeting-adc-platform-with-clinical-data-from-zw191-at-aacr-2026 2026-03-18T01:07:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-advances-novel-ras-targeting-adc-platform-with-clinical-data-from-zw191-at-aacr-2026 2026-03-18T01:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/immunitas-therapeutics-to-present-first-in-human-data-for-novel-anti-cd161-antibody-imt-009-at-aacr-2026 2026-03-18T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitas-therapeutics-to-present-first-in-human-data-for-novel-anti-cd161-antibody-imt-009-at-aacr-2026 2026-03-18T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/blossomhill-therapeutics-unveils-next-generation-pan-kras-inhibitors-with-picomolar-potency-at-aacr-2026 2026-03-18T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blossomhill-therapeutics-unveils-next-generation-pan-kras-inhibitors-with-picomolar-potency-at-aacr-2026 2026-03-18T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-orders-patent-office-to-resolve-novartis-breast-cancer-drug-application-after-13-year-delay 2026-03-18T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-orders-patent-office-to-resolve-novartis-breast-cancer-drug-application-after-13-year-delay 2026-03-18T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/peijia-medical-s-dcwire-micro-guidewire-receives-first-fda-510-k-clearance-opening-u-s-market-entry 2026-03-18T01:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peijia-medical-s-dcwire-micro-guidewire-receives-first-fda-510-k-clearance-opening-u-s-market-entry 2026-03-18T01:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-reports-first-clinical-data-for-novel-multi-chain-kir-car-therapies-at-aacr-2026 2026-03-18T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-reports-first-clinical-data-for-novel-multi-chain-kir-car-therapies-at-aacr-2026 2026-03-18T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/sionna-therapeutics-advances-cftr-modulators-for-cystic-fibrosis-with-strong-analyst-support-and-summer-data-readouts 2026-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sionna-therapeutics-advances-cftr-modulators-for-cystic-fibrosis-with-strong-analyst-support-and-summer-data-readouts 2026-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-and-exact-sciences-present-breakthrough-multi-cancer-early-detection-data-at-aacr-2026 2026-03-17T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-and-exact-sciences-present-breakthrough-multi-cancer-early-detection-data-at-aacr-2026 2026-03-17T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/r1-therapeutics-launches-with-77-5-million-series-a-to-develop-novel-chronic-kidney-disease-treatment 2026-03-17T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r1-therapeutics-launches-with-77-5-million-series-a-to-develop-novel-chronic-kidney-disease-treatment 2026-03-17T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/act-capital-management-invests-8-million-in-tg-therapeutics-despite-30-stock-decline 2026-03-17T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/act-capital-management-invests-8-million-in-tg-therapeutics-despite-30-stock-decline 2026-03-17T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-real-world-analysis-validates-immunowell-jcv-test-for-pml-risk-assessment-in-multiple-sclerosis-patients 2026-03-17T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-european-real-world-analysis-validates-immunowell-jcv-test-for-pml-risk-assessment-in-multiple-sclerosis-patients 2026-03-17T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-allogeneic-car-t-therapy-shows-promising-durability-data-in-latest-clinical-update 2026-03-17T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-allogeneic-car-t-therapy-shows-promising-durability-data-in-latest-clinical-update 2026-03-17T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-scientists-discover-fructose-metabolism-pathway-drives-glioblastoma-growth-and-immune-suppression 2026-03-17T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-scientists-discover-fructose-metabolism-pathway-drives-glioblastoma-growth-and-immune-suppression 2026-03-17T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-receives-nmpa-approval-for-first-in-class-osteoarthritis-drug-trd221-clinical-trial 2026-03-17T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharmaceutical-receives-nmpa-approval-for-first-in-class-osteoarthritis-drug-trd221-clinical-trial 2026-03-17T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-and-takeda-pharmaceutical-strengthen-research-partnership-to-advance-clinical-trials-and-drug-access 2026-03-17T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-and-takeda-pharmaceutical-strengthen-research-partnership-to-advance-clinical-trials-and-drug-access 2026-03-17T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-data-confirm-sustained-survival-benefits-of-pd-1-inhibitors-in-nasopharyngeal-and-esophageal-cancers 2026-03-17T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-follow-up-data-confirm-sustained-survival-benefits-of-pd-1-inhibitors-in-nasopharyngeal-and-esophageal-cancers 2026-03-17T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/nice-suspends-resminostat-appraisal-after-company-withdraws-marketing-authorization-application 2026-03-17T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-suspends-resminostat-appraisal-after-company-withdraws-marketing-authorization-application 2026-03-17T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-reports-long-term-hpv-vaccine-efficacy-data-spanning-up-to-18-years 2026-03-17T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-reports-long-term-hpv-vaccine-efficacy-data-spanning-up-to-18-years 2026-03-17T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/uc-berkeley-researchers-develop-machine-learning-methods-to-accelerate-drug-development-using-real-world-evidence 2026-03-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-berkeley-researchers-develop-machine-learning-methods-to-accelerate-drug-development-using-real-world-evidence 2026-03-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/cellprothera-advances-protheracytes-stem-cell-therapy-to-phase-iii-for-post-mi-heart-failure 2026-03-17T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellprothera-advances-protheracytes-stem-cell-therapy-to-phase-iii-for-post-mi-heart-failure 2026-03-17T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/asimov-partners-with-score-pharma-to-develop-enhanced-anti-her2-antibody-therapeutics-for-breast-cancer 2026-03-17T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asimov-partners-with-score-pharma-to-develop-enhanced-anti-her2-antibody-therapeutics-for-breast-cancer 2026-03-17T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/voro-therapeutics-partners-with-daiichi-sankyo-to-develop-tumor-activated-adcs-using-primebody-platform 2026-03-17T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voro-therapeutics-partners-with-daiichi-sankyo-to-develop-tumor-activated-adcs-using-primebody-platform 2026-03-17T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-chronos-platform-detects-parkinson-s-disease-biomarkers-up-to-12-years-before-clinical-diagnosis 2026-03-17T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-chronos-platform-detects-parkinson-s-disease-biomarkers-up-to-12-years-before-clinical-diagnosis 2026-03-17T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-s-177lu-sn201-shows-continued-safety-in-phase-i-iia-trial-across-multiple-solid-tumors 2026-03-17T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spago-nanomedical-s-177lu-sn201-shows-continued-safety-in-phase-i-iia-trial-across-multiple-solid-tumors 2026-03-17T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-appoints-liahna-toy-to-lead-global-early-phase-center-of-excellence 2026-03-17T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avance-clinical-appoints-liahna-toy-to-lead-global-early-phase-center-of-excellence 2026-03-17T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/vst-bio-secures-45m-series-a-to-advance-first-in-class-stroke-therapeutic-vb-001-into-human-trials 2026-03-17T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vst-bio-secures-45m-series-a-to-advance-first-in-class-stroke-therapeutic-vb-001-into-human-trials 2026-03-17T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-bio-partners-with-terumo-to-automate-regulatory-t-cell-manufacturing-for-transplant-therapy 2026-03-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-bio-partners-with-terumo-to-automate-regulatory-t-cell-manufacturing-for-transplant-therapy 2026-03-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/osm-car-t-therapy-shows-promise-against-osteosarcoma-in-preclinical-studies 2026-03-17T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osm-car-t-therapy-shows-promise-against-osteosarcoma-in-preclinical-studies 2026-03-17T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/alzpath-s-ptau217-antibody-gains-widespread-validation-at-ad-pd-2026-conference 2026-03-17T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzpath-s-ptau217-antibody-gains-widespread-validation-at-ad-pd-2026-conference 2026-03-17T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/idel-therapeutics-raises-eur9-million-to-advance-direct-cytosolic-drug-delivery-platform-for-cancer-treatment 2026-03-17T17:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idel-therapeutics-raises-eur9-million-to-advance-direct-cytosolic-drug-delivery-platform-for-cancer-treatment 2026-03-17T17:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-plans-phase-1-trial-of-iba101-cd47-blocking-antibody-for-lung-cancer 2026-03-17T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liminatus-pharma-plans-phase-1-trial-of-iba101-cd47-blocking-antibody-for-lung-cancer 2026-03-17T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/innorna-receives-fda-clearance-for-first-in-class-mrna-therapy-in026-targeting-refractory-gout 2026-03-17T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innorna-receives-fda-clearance-for-first-in-class-mrna-therapy-in026-targeting-refractory-gout 2026-03-17T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/start-partners-with-trialing-to-expand-access-to-oncology-clinical-trials-across-europe 2026-03-17T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/start-partners-with-trialing-to-expand-access-to-oncology-clinical-trials-across-europe 2026-03-17T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-aldeyra-s-dry-eye-disease-drug-reproxalap-for-third-time-citing-insufficient-efficacy 2026-03-17T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-aldeyra-s-dry-eye-disease-drug-reproxalap-for-third-time-citing-insufficient-efficacy 2026-03-17T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-uncover-how-lecanemab-activates-brain-s-immune-cells-to-clear-alzheimer-s-plaques 2026-03-17T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-uncover-how-lecanemab-activates-brain-s-immune-cells-to-clear-alzheimer-s-plaques 2026-03-17T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/pixelgen-technologies-partners-with-karolinska-institutet-to-discover-novel-biomarkers-for-cancer-immunotherapy-response 2026-03-17T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pixelgen-technologies-partners-with-karolinska-institutet-to-discover-novel-biomarkers-for-cancer-immunotherapy-response 2026-03-17T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-review-finds-no-evidence-of-medicinal-cannabis-efficacy-for-major-mental-health-disorders 2026-03-17T13:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-review-finds-no-evidence-of-medicinal-cannabis-efficacy-for-major-mental-health-disorders 2026-03-17T13:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-secures-ps7-5m-funding-to-advance-kapiglucagon-for-type-1-diabetes-artificial-pancreas-systems 2026-03-17T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immupharma-secures-ps7-5m-funding-to-advance-kapiglucagon-for-type-1-diabetes-artificial-pancreas-systems 2026-03-17T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/crism-therapeutics-secures-fda-orphan-drug-designation-for-brain-cancer-treatment 2026-03-17T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crism-therapeutics-secures-fda-orphan-drug-designation-for-brain-cancer-treatment 2026-03-17T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/sequential-secures-3-5m-to-develop-ai-powered-platform-for-skin-health-biomarker-discovery 2026-03-17T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequential-secures-3-5m-to-develop-ai-powered-platform-for-skin-health-biomarker-discovery 2026-03-17T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/outrun-therapeutics-advances-first-in-class-e6ap-inhibitor-for-hpv-positive-head-and-neck-cancer 2026-03-17T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outrun-therapeutics-advances-first-in-class-e6ap-inhibitor-for-hpv-positive-head-and-neck-cancer 2026-03-17T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/merck-presents-positive-phase-3-data-for-oral-pcsk9-inhibitor-enlicitide-at-acc-26 2026-03-17T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-presents-positive-phase-3-data-for-oral-pcsk9-inhibitor-enlicitide-at-acc-26 2026-03-17T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/r1-therapeutics-launches-with-77-5m-to-develop-novel-kidney-disease-treatment 2026-03-17T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r1-therapeutics-launches-with-77-5m-to-develop-novel-kidney-disease-treatment 2026-03-17T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/soley-therapeutics-develops-first-in-class-ckap2-modulator-stx-6398-for-cancer-treatment 2026-03-17T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soley-therapeutics-develops-first-in-class-ckap2-modulator-stx-6398-for-cancer-treatment 2026-03-17T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iron-mediated-ferroptosis-impairs-car-t-cell-function-and-antitumor-efficacy-in-multiple-myeloma 2026-03-17T09:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iron-mediated-ferroptosis-impairs-car-t-cell-function-and-antitumor-efficacy-in-multiple-myeloma 2026-03-17T09:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/lightbridge-secures-key-patent-approvals-for-advanced-nuclear-fuel-technology-in-canada-and-europe 2026-03-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lightbridge-secures-key-patent-approvals-for-advanced-nuclear-fuel-technology-in-canada-and-europe 2026-03-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jamp-pharma-group-launches-generic-enzalutamide-for-prostate-cancer-treatment-in-canada 2026-03-17T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jamp-pharma-group-launches-generic-enzalutamide-for-prostate-cancer-treatment-in-canada 2026-03-17T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/england-launches-one-off-menb-vaccination-programme-for-students-ahead-of-2026-academic-year 2026-03-17T03:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/england-launches-one-off-menb-vaccination-programme-for-students-ahead-of-2026-academic-year 2026-03-17T03:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-bacteria-to-transform-plastic-waste-into-parkinson-s-drug-l-dopa 2026-03-17T01:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-engineer-bacteria-to-transform-plastic-waste-into-parkinson-s-drug-l-dopa 2026-03-17T01:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/dual-drug-combinations-show-promise-in-overcoming-multiple-myeloma-resistance 2026-03-17T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-drug-combinations-show-promise-in-overcoming-multiple-myeloma-resistance 2026-03-17T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/pyc-therapeutics-advances-two-rna-based-therapies-for-inherited-blindness-conditions 2026-03-17T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyc-therapeutics-advances-two-rna-based-therapies-for-inherited-blindness-conditions 2026-03-17T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-completes-11-billion-bond-sale-to-finance-avidity-biosciences-acquisition 2026-03-17T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-completes-11-billion-bond-sale-to-finance-avidity-biosciences-acquisition 2026-03-17T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-advances-bispecific-antibody-for-pulmonary-hypertension-in-heart-failure-targets-q3-2026-development-candidate 2026-03-17T01:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-advances-bispecific-antibody-for-pulmonary-hypertension-in-heart-failure-targets-q3-2026-development-candidate 2026-03-17T01:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/aptar-s-intranasal-delivery-system-advances-ltr-pharma-s-spontan-phase-ii-trial-for-erectile-dysfunction 2026-03-17T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptar-s-intranasal-delivery-system-advances-ltr-pharma-s-spontan-phase-ii-trial-for-erectile-dysfunction 2026-03-17T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/gnq-insilico-to-go-public-through-500m-spac-deal-advancing-ai-powered-drug-development-platforms 2026-03-17T01:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gnq-insilico-to-go-public-through-500m-spac-deal-advancing-ai-powered-drug-development-platforms 2026-03-17T01:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-announces-us-launch-of-potassium-phosphates-injection-for-hypophosphatemia-treatment 2026-03-17T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-announces-us-launch-of-potassium-phosphates-injection-for-hypophosphatemia-treatment 2026-03-17T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/datatrak-and-tailrd-heart-form-strategic-partnership-to-advance-ai-driven-cardiovascular-clinical-research 2026-03-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datatrak-and-tailrd-heart-form-strategic-partnership-to-advance-ai-driven-cardiovascular-clinical-research 2026-03-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-debuts-on-hong-kong-exchange-as-world-s-first-publicly-listed-ai-powered-drug-delivery-company 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-techbio-debuts-on-hong-kong-exchange-as-world-s-first-publicly-listed-ai-powered-drug-delivery-company 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/briohealth-reaches-100-briovad-implants-gains-fda-approval-for-pediatric-heart-failure-trial 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/briohealth-reaches-100-briovad-implants-gains-fda-approval-for-pediatric-heart-failure-trial 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/bulgold-closes-1-17-million-private-placement-to-advance-slovak-gold-project-development 2026-03-16T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bulgold-closes-1-17-million-private-placement-to-advance-slovak-gold-project-development 2026-03-16T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/solve-gne-advances-first-gene-therapy-for-gne-myopathy-toward-phase-i-clinical-trial 2026-03-16T21:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solve-gne-advances-first-gene-therapy-for-gne-myopathy-toward-phase-i-clinical-trial 2026-03-16T21:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-launches-phase-i-clinical-trial-to-determine-optimal-thc-dosing-for-anxiety-treatment 2026-03-16T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avicanna-launches-phase-i-clinical-trial-to-determine-optimal-thc-dosing-for-anxiety-treatment 2026-03-16T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/sona-nanotech-s-targeted-hyperthermia-therapy-shows-38-tumor-clearance-in-colorectal-cancer-study 2026-03-16T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sona-nanotech-s-targeted-hyperthermia-therapy-shows-38-tumor-clearance-in-colorectal-cancer-study 2026-03-16T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-unveils-eveo-platform-to-transform-cell-therapy-manufacturing-with-90-cost-reduction 2026-03-16T21:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sartorius-unveils-eveo-platform-to-transform-cell-therapy-manufacturing-with-90-cost-reduction 2026-03-16T21:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/neximmune-advances-nex-ile12-immunotherapy-in-phase-1-trials-with-promising-safety-profile 2026-03-16T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neximmune-advances-nex-ile12-immunotherapy-in-phase-1-trials-with-promising-safety-profile 2026-03-16T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-first-formal-guidance-on-form-483-response-requirements-for-drug-manufacturers 2026-03-16T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-first-formal-guidance-on-form-483-response-requirements-for-drug-manufacturers 2026-03-16T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/egret-therapeutics-moves-to-acquire-full-ownership-of-first-in-class-pd-1-agonist-for-stroke-related-brain-swelling 2026-03-16T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egret-therapeutics-moves-to-acquire-full-ownership-of-first-in-class-pd-1-agonist-for-stroke-related-brain-swelling 2026-03-16T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/prodeon-medical-s-urocross-expander-system-receives-fda-clearance-for-non-permanent-bph-treatment 2026-03-16T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prodeon-medical-s-urocross-expander-system-receives-fda-clearance-for-non-permanent-bph-treatment 2026-03-16T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-reports-promising-phase-2-data-for-silevertinib-in-egfr-mutant-cancers 2026-03-16T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-diamond-therapeutics-reports-promising-phase-2-data-for-silevertinib-in-egfr-mutant-cancers 2026-03-16T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/blue-light-cystoscopy-shows-superior-detection-and-cost-effectiveness-in-high-risk-bladder-cancer-management 2026-03-16T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-light-cystoscopy-shows-superior-detection-and-cost-effectiveness-in-high-risk-bladder-cancer-management 2026-03-16T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/amlogenyx-reports-promising-preclinical-data-for-am805-gene-therapy-in-alzheimer-s-disease-treatment 2026-03-16T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amlogenyx-reports-promising-preclinical-data-for-am805-gene-therapy-in-alzheimer-s-disease-treatment 2026-03-16T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/avethera-gmbh-acquires-fraunhofer-item-braunschweig-site-to-expand-biopharmaceutical-manufacturing 2026-03-16T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avethera-gmbh-acquires-fraunhofer-item-braunschweig-site-to-expand-biopharmaceutical-manufacturing 2026-03-16T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/ternary-therapeutics-secures-ps3-6m-to-advance-ai-driven-molecular-glue-drug-discovery-platform 2026-03-16T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ternary-therapeutics-secures-ps3-6m-to-advance-ai-driven-molecular-glue-drug-discovery-platform 2026-03-16T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-partners-with-veritas-genetics-to-integrate-whole-genome-sequencing-into-health-insurance-plans 2026-03-16T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-partners-with-veritas-genetics-to-integrate-whole-genome-sequencing-into-health-insurance-plans 2026-03-16T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/sentynl-therapeutics-licenses-progerinin-for-hutchinson-gilford-progeria-syndrome-treatment 2026-03-16T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sentynl-therapeutics-licenses-progerinin-for-hutchinson-gilford-progeria-syndrome-treatment 2026-03-16T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/elevara-medicines-initiates-phase-2b-trial-of-novel-cdk4-6-inhibitor-elv001-for-treatment-resistant-rheumatoid-arthritis 2026-03-16T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevara-medicines-initiates-phase-2b-trial-of-novel-cdk4-6-inhibitor-elv001-for-treatment-resistant-rheumatoid-arthritis 2026-03-16T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-reports-positive-phase-1b-results-for-lu-af28996-in-advanced-parkinson-s-disease 2026-03-16T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-reports-positive-phase-1b-results-for-lu-af28996-in-advanced-parkinson-s-disease 2026-03-16T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-shows-96-accuracy-in-detecting-glioblastoma-offering-hope-for-earlier-diagnosis 2026-03-16T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-shows-96-accuracy-in-detecting-glioblastoma-offering-hope-for-earlier-diagnosis 2026-03-16T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/scinus-group-secures-eur3-million-to-advance-cell-therapy-manufacturing-platform 2026-03-16T13:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinus-group-secures-eur3-million-to-advance-cell-therapy-manufacturing-platform 2026-03-16T13:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/grit-biotechnologies-receives-fda-ind-clearance-for-gene-edited-til-therapy-gt307 2026-03-16T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grit-biotechnologies-receives-fda-ind-clearance-for-gene-edited-til-therapy-gt307 2026-03-16T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/organoid-science-receives-world-s-first-ind-approval-for-intestinal-organoid-therapy-in-crohn-s-disease 2026-03-16T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organoid-science-receives-world-s-first-ind-approval-for-intestinal-organoid-therapy-in-crohn-s-disease 2026-03-16T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/super-vision-technology-s-i-nys-implant-receives-china-approval-as-world-s-first-treatment-for-congenital-nystagmus 2026-03-16T13:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/super-vision-technology-s-i-nys-implant-receives-china-approval-as-world-s-first-treatment-for-congenital-nystagmus 2026-03-16T13:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-achieves-major-adc-manufacturing-milestone-with-1500th-batch-delivery 2026-03-16T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-achieves-major-adc-manufacturing-milestone-with-1500th-batch-delivery 2026-03-16T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-protein-carrier-boosts-paclitaxel-solubility-3600-fold-in-targeted-cancer-therapy 2026-03-16T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-protein-carrier-boosts-paclitaxel-solubility-3600-fold-in-targeted-cancer-therapy 2026-03-16T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/gen-pharmaceuticals-receives-ethical-approval-for-phase-ii-parkinson-s-disease-trial-of-mitochondrial-targeting-drug-sul-238 2026-03-16T09:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gen-pharmaceuticals-receives-ethical-approval-for-phase-ii-parkinson-s-disease-trial-of-mitochondrial-targeting-drug-sul-238 2026-03-16T09:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-finerenone-achieves-primary-endpoint-in-phase-iii-find-ckd-trial-for-non-diabetic-chronic-kidney-disease 2026-03-16T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-finerenone-achieves-primary-endpoint-in-phase-iii-find-ckd-trial-for-non-diabetic-chronic-kidney-disease 2026-03-16T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-industry-leaders-call-for-systemic-change-to-address-persistent-gender-gap-in-stem 2026-03-16T06:26:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-industry-leaders-call-for-systemic-change-to-address-persistent-gender-gap-in-stem 2026-03-16T06:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/cutia-therapeutics-receives-nmpa-approval-for-topical-dutasteride-clinical-trial-in-androgenetic-alopecia 2026-03-16T05:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cutia-therapeutics-receives-nmpa-approval-for-topical-dutasteride-clinical-trial-in-androgenetic-alopecia 2026-03-16T05:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/tetratherix-launches-precision-medicine-platform-with-30m-partnership-for-nasal-drug-delivery 2026-03-16T05:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tetratherix-launches-precision-medicine-platform-with-30m-partnership-for-nasal-drug-delivery 2026-03-16T05:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-advances-autism-diagnostic-device-toward-fda-clearance-with-pivotal-trial-launch 2026-03-16T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinklab-advances-autism-diagnostic-device-toward-fda-clearance-with-pivotal-trial-launch 2026-03-16T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-raises-2-2-million-to-advance-vista-targeting-cancer-therapy-hmbd-002 2026-03-16T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-raises-2-2-million-to-advance-vista-targeting-cancer-therapy-hmbd-002 2026-03-16T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/racura-oncology-receives-approval-for-phase-1-trial-of-rc220-combination-therapy-in-egfr-mutant-lung-cancer 2026-03-16T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racura-oncology-receives-approval-for-phase-1-trial-of-rc220-combination-therapy-in-egfr-mutant-lung-cancer 2026-03-16T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-mrna-cancer-vaccine-shows-promise-in-canine-trial-sparks-human-treatment-potential 2026-03-15T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-mrna-cancer-vaccine-shows-promise-in-canine-trial-sparks-human-treatment-potential 2026-03-15T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/firefly-neuroscience-discovers-brain-wave-biomarkers-to-distinguish-adhd-subtypes 2026-03-14T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/firefly-neuroscience-discovers-brain-wave-biomarkers-to-distinguish-adhd-subtypes 2026-03-14T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-completes-two-key-oncology-studies-as-pipeline-advances 2026-03-14T21:05:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharmaceutical-completes-two-key-oncology-studies-as-pipeline-advances 2026-03-14T21:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/fibrogen-refocuses-on-oncology-pipeline-following-china-divestiture-extends-runway-through-2028 2026-03-14T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrogen-refocuses-on-oncology-pipeline-following-china-divestiture-extends-runway-through-2028 2026-03-14T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-engineer-bacteria-to-boost-doxorubicin-production-by-180-overcoming-50-year-manufacturing-challenge 2026-03-14T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-engineer-bacteria-to-boost-doxorubicin-production-by-180-overcoming-50-year-manufacturing-challenge 2026-03-14T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/uk-patient-becomes-first-to-receive-experimental-antibody-drug-conjugate-for-metastatic-prostate-cancer 2026-03-14T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-patient-becomes-first-to-receive-experimental-antibody-drug-conjugate-for-metastatic-prostate-cancer 2026-03-14T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/duke-clinical-trial-shows-promising-results-for-first-line-immunotherapy-in-metastatic-colorectal-cancer 2026-03-14T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-clinical-trial-shows-promising-results-for-first-line-immunotherapy-in-metastatic-colorectal-cancer 2026-03-14T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biotech-companies-to-showcase-next-generation-cancer-therapies-at-aacr-2026 2026-03-14T13:03:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-biotech-companies-to-showcase-next-generation-cancer-therapies-at-aacr-2026 2026-03-14T13:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-amie-ai-assistant-demonstrates-doctor-level-diagnostic-performance-in-first-real-world-clinical-trial 2026-03-14T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-amie-ai-assistant-demonstrates-doctor-level-diagnostic-performance-in-first-real-world-clinical-trial 2026-03-14T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/vimgreen-s-a2a-receptor-antagonist-vg081821-receives-first-global-ind-approval-for-nash-treatment 2026-03-14T09:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vimgreen-s-a2a-receptor-antagonist-vg081821-receives-first-global-ind-approval-for-nash-treatment 2026-03-14T09:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/hawkeye-bio-secures-patent-for-graphene-biosensor-platform-targeting-early-lung-cancer-detection 2026-03-14T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hawkeye-bio-secures-patent-for-graphene-biosensor-platform-targeting-early-lung-cancer-detection 2026-03-14T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/combat-medical-advances-hivec-heat-trial-for-bcg-unresponsive-bladder-cancer-with-ps2-6-million-series-a-funding 2026-03-14T06:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combat-medical-advances-hivec-heat-trial-for-bcg-unresponsive-bladder-cancer-with-ps2-6-million-series-a-funding 2026-03-14T06:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/duke-engineers-develop-sonopin-technology-to-enhance-delivery-of-large-cancer-therapeutics 2026-03-14T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-engineers-develop-sonopin-technology-to-enhance-delivery-of-large-cancer-therapeutics 2026-03-14T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-recommends-including-subclade-k-variant-in-fall-2024-flu-vaccines 2026-03-14T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-recommends-including-subclade-k-variant-in-fall-2024-flu-vaccines 2026-03-14T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/hydracs-protein-like-polymers-open-new-frontier-in-targeted-protein-degradation-for-undruggable-cancer-targets 2026-03-13T21:11:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydracs-protein-like-polymers-open-new-frontier-in-targeted-protein-degradation-for-undruggable-cancer-targets 2026-03-13T21:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/eliquis-demonstrates-superior-safety-profile-over-xarelto-in-direct-comparison-trial-for-venous-thrombosis 2026-03-13T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eliquis-demonstrates-superior-safety-profile-over-xarelto-in-direct-comparison-trial-for-venous-thrombosis 2026-03-13T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/einstein-scientists-develop-novel-car-t-manufacturing-method-to-extend-therapeutic-durability 2026-03-13T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/einstein-scientists-develop-novel-car-t-manufacturing-method-to-extend-therapeutic-durability 2026-03-13T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-erda-idrs-shows-89-complete-response-rate-in-first-in-human-bladder-cancer-study 2026-03-13T21:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-erda-idrs-shows-89-complete-response-rate-in-first-in-human-bladder-cancer-study 2026-03-13T21:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-ag-secures-eur650m-biosimilar-partnership-with-athos-kg-in-landmark-deal 2026-03-13T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-ag-secures-eur650m-biosimilar-partnership-with-athos-kg-in-landmark-deal 2026-03-13T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-bio-s-ai-platform-achieves-breakthrough-in-drug-target-prediction-with-92-accuracy 2026-03-13T21:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tevogen-bio-s-ai-platform-achieves-breakthrough-in-drug-target-prediction-with-92-accuracy 2026-03-13T21:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-cosentyx-for-pediatric-hidradenitis-suppurativa-marking-first-il-17a-inhibitor-for-adolescents 2026-03-13T21:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-cosentyx-for-pediatric-hidradenitis-suppurativa-marking-first-il-17a-inhibitor-for-adolescents 2026-03-13T21:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-completes-strategic-transformation-with-3-billion-divestment-of-capsules-health-ingredients-business 2026-03-13T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-completes-strategic-transformation-with-3-billion-divestment-of-capsules-health-ingredients-business 2026-03-13T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/unixell-biotech-receives-fda-ind-clearance-for-first-ipsc-derived-allogeneic-cell-therapy-for-focal-epilepsy 2026-03-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unixell-biotech-receives-fda-ind-clearance-for-first-ipsc-derived-allogeneic-cell-therapy-for-focal-epilepsy 2026-03-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/barinthus-bio-completes-phase-1-celiac-disease-trial-as-company-prepares-for-strategic-merger 2026-03-13T17:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barinthus-bio-completes-phase-1-celiac-disease-trial-as-company-prepares-for-strategic-merger 2026-03-13T17:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-achieves-manufacturing-breakthrough-for-nk-cell-therapy-platform-with-scalable-production-process 2026-03-13T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-achieves-manufacturing-breakthrough-for-nk-cell-therapy-platform-with-scalable-production-process 2026-03-13T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/insulet-recalls-omnipod-5-insulin-pumps-after-18-serious-adverse-events-due-to-internal-tubing-defect 2026-03-13T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insulet-recalls-omnipod-5-insulin-pumps-after-18-serious-adverse-events-due-to-internal-tubing-defect 2026-03-13T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-desidustat-tablets-for-renal-anemia-addressing-critical-treatment-gap-in-ckd-patients 2026-03-13T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-desidustat-tablets-for-renal-anemia-addressing-critical-treatment-gap-in-ckd-patients 2026-03-13T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/aditxt-acquires-ignite-proteomics-for-36-million-to-advance-precision-oncology-platform 2026-03-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aditxt-acquires-ignite-proteomics-for-36-million-to-advance-precision-oncology-platform 2026-03-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/fridge-free-tetanus-and-diphtheria-vaccine-shows-promise-in-phase-1-trials-advances-to-next-clinical-stage 2026-03-13T17:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fridge-free-tetanus-and-diphtheria-vaccine-shows-promise-in-phase-1-trials-advances-to-next-clinical-stage 2026-03-13T17:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-world-s-first-commercial-brain-computer-interface-for-spinal-cord-injury-treatment 2026-03-13T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-world-s-first-commercial-brain-computer-interface-for-spinal-cord-injury-treatment 2026-03-13T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/who-releases-target-product-profiles-to-guide-development-of-antibiotics-against-priority-pathogens 2026-03-13T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-releases-target-product-profiles-to-guide-development-of-antibiotics-against-priority-pathogens 2026-03-13T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/century-health-partners-with-dallas-renal-group-to-advance-ai-driven-research-in-rare-kidney-diseases 2026-03-13T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-health-partners-with-dallas-renal-group-to-advance-ai-driven-research-in-rare-kidney-diseases 2026-03-13T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/topical-cream-activates-skin-s-immune-system-to-suppress-cutaneous-squamous-cell-carcinoma-growth 2026-03-13T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topical-cream-activates-skin-s-immune-system-to-suppress-cutaneous-squamous-cell-carcinoma-growth 2026-03-13T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/major-insurers-expand-coverage-for-peripheral-nerve-stimulation-systems-improving-access-for-chronic-pain-patients 2026-03-13T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-insurers-expand-coverage-for-peripheral-nerve-stimulation-systems-improving-access-for-chronic-pain-patients 2026-03-13T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/penn-spinout-linnaeus-therapeutics-secures-22-million-federal-grant-to-advance-anti-aging-drug-lns8801 2026-03-13T09:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-spinout-linnaeus-therapeutics-secures-22-million-federal-grant-to-advance-anti-aging-drug-lns8801 2026-03-13T09:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/creative-biolabs-advances-mrna-therapeutics-with-novel-lnp-conjugation-and-lpp-delivery-platforms 2026-03-13T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-biolabs-advances-mrna-therapeutics-with-novel-lnp-conjugation-and-lpp-delivery-platforms 2026-03-13T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/colombia-partners-with-3pbiovian-to-develop-first-domestic-biosimilar-cancer-drug 2026-03-13T09:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colombia-partners-with-3pbiovian-to-develop-first-domestic-biosimilar-cancer-drug 2026-03-13T09:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/elicio-therapeutics-reports-encouraging-phase-2-amplify-7p-trial-progress-with-fewer-disease-events-than-projected 2026-03-13T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicio-therapeutics-reports-encouraging-phase-2-amplify-7p-trial-progress-with-fewer-disease-events-than-projected 2026-03-13T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/eve-health-group-secures-904000-to-advance-reformulated-pharmaceutical-pipeline 2026-03-13T05:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eve-health-group-secures-904000-to-advance-reformulated-pharmaceutical-pipeline 2026-03-13T05:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-halts-phase-iii-lung-cancer-trial-after-futility-analysis-shares-plunge-88 2026-03-13T05:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-halts-phase-iii-lung-cancer-trial-after-futility-analysis-shares-plunge-88 2026-03-13T05:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/immunobrain-reports-phase-1b-results-for-novel-pd-l1-checkpoint-inhibitor-in-alzheimer-s-disease 2026-03-13T02:41:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunobrain-reports-phase-1b-results-for-novel-pd-l1-checkpoint-inhibitor-in-alzheimer-s-disease 2026-03-13T02:41:01+00:00 hourly 0.9 https://trial.medpath.com/news/waiv-raises-33m-to-scale-ai-powered-cancer-precision-testing-platform-globally 2026-03-13T02:39:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waiv-raises-33m-to-scale-ai-powered-cancer-precision-testing-platform-globally 2026-03-13T02:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-appoints-karen-basbaum-as-chief-business-officer-to-drive-strategic-partnerships 2026-03-12T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-appoints-karen-basbaum-as-chief-business-officer-to-drive-strategic-partnerships 2026-03-12T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/foundation-medicine-expands-beyond-oncology-with-whole-genome-sequencing-test-for-cardiometabolic-and-neurologic-diseases 2026-03-12T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foundation-medicine-expands-beyond-oncology-with-whole-genome-sequencing-test-for-cardiometabolic-and-neurologic-diseases 2026-03-12T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/costco-partners-with-sesame-and-ivi-rma-to-transform-fertility-care-access-with-80-medication-savings 2026-03-12T21:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/costco-partners-with-sesame-and-ivi-rma-to-transform-fertility-care-access-with-80-medication-savings 2026-03-12T21:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-and-sanofi-settle-decade-long-patent-dispute-over-pcsk9-cholesterol-drugs 2026-03-12T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-and-sanofi-settle-decade-long-patent-dispute-over-pcsk9-cholesterol-drugs 2026-03-12T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/vienna-s-valanx-biotech-secures-eur3-million-to-advance-precision-adc-platform-for-triple-negative-breast-cancer 2026-03-12T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vienna-s-valanx-biotech-secures-eur3-million-to-advance-precision-adc-platform-for-triple-negative-breast-cancer 2026-03-12T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocurie-secures-9-3m-arpa-h-award-to-develop-ai-powered-gene-therapy-manufacturing-platform 2026-03-12T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocurie-secures-9-3m-arpa-h-award-to-develop-ai-powered-gene-therapy-manufacturing-platform 2026-03-12T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/psiquantum-partners-with-national-cancer-center-japan-to-advance-quantum-computing-in-drug-discovery 2026-03-12T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psiquantum-partners-with-national-cancer-center-japan-to-advance-quantum-computing-in-drug-discovery 2026-03-12T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/structured-exercise-program-reduces-chemo-brain-in-phase-3-trial 2026-03-12T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structured-exercise-program-reduces-chemo-brain-in-phase-3-trial 2026-03-12T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-medications-linked-to-nutrient-deficiencies-and-emerging-health-complications 2026-03-12T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-medications-linked-to-nutrient-deficiencies-and-emerging-health-complications 2026-03-12T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/mestag-therapeutics-to-present-novel-ltbr-agonist-mst-0312-data-at-cancer-immunotherapy-symposium 2026-03-12T17:11:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mestag-therapeutics-to-present-novel-ltbr-agonist-mst-0312-data-at-cancer-immunotherapy-symposium 2026-03-12T17:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/rice-university-bioengineer-receives-2-2m-gates-foundation-grant-for-revolutionary-long-acting-cell-factory-implants 2026-03-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rice-university-bioengineer-receives-2-2m-gates-foundation-grant-for-revolutionary-long-acting-cell-factory-implants 2026-03-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/nsw-opens-96-million-rna-manufacturing-facility-as-university-of-sydney-spinout-secures-tb-vaccine-funding 2026-03-12T17:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsw-opens-96-million-rna-manufacturing-facility-as-university-of-sydney-spinout-secures-tb-vaccine-funding 2026-03-12T17:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/galimedix-achieves-phase-1-milestone-for-oral-gal-101-in-alzheimer-s-disease-development 2026-03-12T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galimedix-achieves-phase-1-milestone-for-oral-gal-101-in-alzheimer-s-disease-development 2026-03-12T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/aplagon-doses-first-patient-in-phase-2a-trial-of-apac-for-chronic-limb-threatening-ischemia 2026-03-12T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aplagon-doses-first-patient-in-phase-2a-trial-of-apac-for-chronic-limb-threatening-ischemia 2026-03-12T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-names-michelle-werner-as-north-america-president-to-drive-growth-strategy 2026-03-12T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-names-michelle-werner-as-north-america-president-to-drive-growth-strategy 2026-03-12T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/natera-launches-zenith-genomics-platform-with-methylation-analysis-for-rare-disease-diagnosis 2026-03-12T17:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-launches-zenith-genomics-platform-with-methylation-analysis-for-rare-disease-diagnosis 2026-03-12T17:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-gene-therapy-dtx301-demonstrates-significant-ammonia-reduction-in-phase-3-otc-deficiency-trial 2026-03-12T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-gene-therapy-dtx301-demonstrates-significant-ammonia-reduction-in-phase-3-otc-deficiency-trial 2026-03-12T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/medically-supervised-ketogenic-diet-extends-survival-by-34-in-metastatic-pancreatic-cancer-patients 2026-03-12T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medically-supervised-ketogenic-diet-extends-survival-by-34-in-metastatic-pancreatic-cancer-patients 2026-03-12T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-scientists-develop-light-driven-method-for-late-stage-drug-modification 2026-03-12T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-scientists-develop-light-driven-method-for-late-stage-drug-modification 2026-03-12T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-receives-fda-approval-for-tecnis-puresee-iol-first-extended-depth-of-focus-lens-without-contrast-sensitivity-warning 2026-03-12T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-receives-fda-approval-for-tecnis-puresee-iol-first-extended-depth-of-focus-lens-without-contrast-sensitivity-warning 2026-03-12T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/soleno-therapeutics-faces-class-action-lawsuit-over-alleged-clinical-trial-integrity-issues-for-prader-willi-syndrome-drug 2026-03-12T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soleno-therapeutics-faces-class-action-lawsuit-over-alleged-clinical-trial-integrity-issues-for-prader-willi-syndrome-drug 2026-03-12T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/cbio-receives-european-clearance-for-first-in-human-trial-of-novel-t-cell-therapy-in-cervical-cancer 2026-03-12T13:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbio-receives-european-clearance-for-first-in-human-trial-of-novel-t-cell-therapy-in-cervical-cancer 2026-03-12T13:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-warns-of-dangerous-impurity-in-compounded-tirzepatide-b12-combinations 2026-03-12T13:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-warns-of-dangerous-impurity-in-compounded-tirzepatide-b12-combinations 2026-03-12T13:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-prime-designation-to-tolerogenixx-s-mic-lx-cell-therapy-for-kidney-transplant-tolerance 2026-03-12T13:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-prime-designation-to-tolerogenixx-s-mic-lx-cell-therapy-for-kidney-transplant-tolerance 2026-03-12T13:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-medical-team-achieves-functional-remission-in-30-type-1-diabetes-patients-through-integrative-medicine-approach 2026-03-12T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-medical-team-achieves-functional-remission-in-30-type-1-diabetes-patients-through-integrative-medicine-approach 2026-03-12T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-reports-promising-early-results-for-int230-6-in-triple-negative-breast-cancer-phase-2-trial 2026-03-12T13:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-reports-promising-early-results-for-int230-6-in-triple-negative-breast-cancer-phase-2-trial 2026-03-12T13:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-partners-with-imperial-and-oxford-to-launch-ps11m-digital-organ-twins-center-for-drug-discovery 2026-03-12T13:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-partners-with-imperial-and-oxford-to-launch-ps11m-digital-organ-twins-center-for-drug-discovery 2026-03-12T13:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/gesynta-pharma-initiates-phase-ii-trial-of-non-hormonal-endometriosis-treatment-vipoglanstat 2026-03-12T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gesynta-pharma-initiates-phase-ii-trial-of-non-hormonal-endometriosis-treatment-vipoglanstat 2026-03-12T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/genscript-opens-first-european-mrna-production-facility-in-netherlands 2026-03-12T09:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genscript-opens-first-european-mrna-production-facility-in-netherlands 2026-03-12T09:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/meiji-seika-pharma-launches-phase-i-trial-of-me3241-novel-pd-1-agonist-for-autoimmune-diseases 2026-03-12T09:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiji-seika-pharma-launches-phase-i-trial-of-me3241-novel-pd-1-agonist-for-autoimmune-diseases 2026-03-12T09:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/huons-advances-novel-dry-eye-treatment-huc1-394-to-phase-2-clinical-trial 2026-03-12T09:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huons-advances-novel-dry-eye-treatment-huc1-394-to-phase-2-clinical-trial 2026-03-12T09:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/preludedx-receives-fda-breakthrough-device-designation-for-aidabreast-multi-omic-test-in-early-stage-breast-cancer 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/preludedx-receives-fda-breakthrough-device-designation-for-aidabreast-multi-omic-test-in-early-stage-breast-cancer 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eau-guidelines-upgrade-aquablation-therapy-to-strong-surgical-recommendation-for-bph-treatment 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eau-guidelines-upgrade-aquablation-therapy-to-strong-surgical-recommendation-for-bph-treatment 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/connected-drug-delivery-devices-market-set-to-reach-12-7-billion-by-2035-driven-by-chronic-disease-rise-and-digital-health-integration 2026-03-12T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/connected-drug-delivery-devices-market-set-to-reach-12-7-billion-by-2035-driven-by-chronic-disease-rise-and-digital-health-integration 2026-03-12T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/apixaban-shows-superior-safety-profile-over-rivaroxaban-in-major-venous-thromboembolism-trial 2026-03-12T05:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apixaban-shows-superior-safety-profile-over-rivaroxaban-in-major-venous-thromboembolism-trial 2026-03-12T05:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/mesoblast-appoints-dr-teresa-montagut-to-lead-clinical-development-and-medical-affairs-for-cell-therapy-expansion 2026-03-12T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesoblast-appoints-dr-teresa-montagut-to-lead-clinical-development-and-medical-affairs-for-cell-therapy-expansion 2026-03-12T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-launches-world-s-first-pediatric-tafenoquine-treatment-for-malaria-in-indigenous-communities 2026-03-12T05:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-launches-world-s-first-pediatric-tafenoquine-treatment-for-malaria-in-indigenous-communities 2026-03-12T05:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/pierre-fabre-s-avene-pioneers-ai-enhanced-clinical-studies-for-acne-treatment-in-dermo-cosmetics 2026-03-12T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pierre-fabre-s-avene-pioneers-ai-enhanced-clinical-studies-for-acne-treatment-in-dermo-cosmetics 2026-03-12T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/proton-beam-therapy-trial-shows-promise-for-mesothelioma-patients-aims-to-double-two-year-survival-rates 2026-03-12T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-beam-therapy-trial-shows-promise-for-mesothelioma-patients-aims-to-double-two-year-survival-rates 2026-03-12T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-advances-deep-brain-stimulation-trial-for-drug-resistant-motor-epilepsy 2026-03-12T01:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-advances-deep-brain-stimulation-trial-for-drug-resistant-motor-epilepsy 2026-03-12T01:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/romiplostim-prevents-chemotherapy-induced-thrombocytopenia-in-phase-3-trial 2026-03-12T01:04:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/romiplostim-prevents-chemotherapy-induced-thrombocytopenia-in-phase-3-trial 2026-03-12T01:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/vitestro-secures-70m-series-b-to-advance-autonomous-blood-collection-robot-for-us-market-entry 2026-03-12T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitestro-secures-70m-series-b-to-advance-autonomous-blood-collection-robot-for-us-market-entry 2026-03-12T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-develops-simplified-nanoparticles-for-in-body-car-t-cell-engineering 2026-03-11T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-develops-simplified-nanoparticles-for-in-body-car-t-cell-engineering 2026-03-11T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-partners-with-neupharma-for-corticorelin-development-in-japan-s-brain-edema-market 2026-03-11T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curatis-partners-with-neupharma-for-corticorelin-development-in-japan-s-brain-edema-market 2026-03-11T21:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/viagra-shows-promise-as-first-treatment-for-fatal-childhood-disease-leigh-syndrome 2026-03-11T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viagra-shows-promise-as-first-treatment-for-fatal-childhood-disease-leigh-syndrome 2026-03-11T21:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/uk-health-authorities-launch-joint-initiative-to-support-infectious-disease-trials-in-africa-and-asia 2026-03-11T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-health-authorities-launch-joint-initiative-to-support-infectious-disease-trials-in-africa-and-asia 2026-03-11T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-introduces-device-access-restrictions-framework-for-flavored-e-cigarette-regulation 2026-03-11T17:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-introduces-device-access-restrictions-framework-for-flavored-e-cigarette-regulation 2026-03-11T17:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/biocorrx-secures-u-s-patent-for-biodegradable-naltrexone-implant-technology 2026-03-11T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocorrx-secures-u-s-patent-for-biodegradable-naltrexone-implant-technology 2026-03-11T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/dna-origami-vaccine-platform-shows-promise-as-next-generation-alternative-to-mrna-vaccines 2026-03-11T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dna-origami-vaccine-platform-shows-promise-as-next-generation-alternative-to-mrna-vaccines 2026-03-11T17:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/spinogenix-completes-enrollment-in-phase-2-trial-of-tazbentetol-for-schizophrenia-treatment 2026-03-11T17:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spinogenix-completes-enrollment-in-phase-2-trial-of-tazbentetol-for-schizophrenia-treatment 2026-03-11T17:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/anacardio-secures-us-patent-for-heart-failure-drug-ac01-extending-protection-until-2042 2026-03-11T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anacardio-secures-us-patent-for-heart-failure-drug-ac01-extending-protection-until-2042 2026-03-11T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-receives-nmpa-approval-for-pan-kras-inhibitor-tqb3205-clinical-trial 2026-03-11T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharmaceutical-receives-nmpa-approval-for-pan-kras-inhibitor-tqb3205-clinical-trial 2026-03-11T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/vima-therapeutics-raises-100m-to-advance-oral-therapy-for-movement-disorders 2026-03-11T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vima-therapeutics-raises-100m-to-advance-oral-therapy-for-movement-disorders 2026-03-11T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-memed-s-ai-powered-infection-test 2026-03-11T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-memed-s-ai-powered-infection-test 2026-03-11T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/arthex-biotech-receives-fda-fast-track-designation-for-atx-01-in-myotonic-dystrophy-type-1 2026-03-11T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arthex-biotech-receives-fda-fast-track-designation-for-atx-01-in-myotonic-dystrophy-type-1 2026-03-11T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/verve-medical-initiates-u-s-pilot-trial-for-novel-renal-denervation-therapy-following-promising-tusk-results 2026-03-11T17:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verve-medical-initiates-u-s-pilot-trial-for-novel-renal-denervation-therapy-following-promising-tusk-results 2026-03-11T17:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/difgen-pharmaceuticals-secures-fda-approval-for-generic-mesalamine-extended-release-capsules 2026-03-11T17:03:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/difgen-pharmaceuticals-secures-fda-approval-for-generic-mesalamine-extended-release-capsules 2026-03-11T17:03:24+00:00 hourly 0.9 https://trial.medpath.com/news/commit-biologics-names-serial-biotech-entrepreneur-as-ceo-to-advance-complement-powered-immunotherapies 2026-03-11T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/commit-biologics-names-serial-biotech-entrepreneur-as-ceo-to-advance-complement-powered-immunotherapies 2026-03-11T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/nice-reverses-decision-approves-genmab-s-tivdak-for-nhs-use-in-cervical-cancer 2026-03-11T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-reverses-decision-approves-genmab-s-tivdak-for-nhs-use-in-cervical-cancer 2026-03-11T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/c2n-diagnostics-expands-alzheimer-s-blood-test-access-across-asia-through-strategic-partnerships 2026-03-11T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c2n-diagnostics-expands-alzheimer-s-blood-test-access-across-asia-through-strategic-partnerships 2026-03-11T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-two-advanced-neurovascular-catheters-for-stroke-and-complex-brain-procedures 2026-03-11T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-two-advanced-neurovascular-catheters-for-stroke-and-complex-brain-procedures 2026-03-11T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmather-advances-microneedle-patch-platform-for-therapeutic-peptides-with-patchprint-manufacturing-system 2026-03-11T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmather-advances-microneedle-patch-platform-for-therapeutic-peptides-with-patchprint-manufacturing-system 2026-03-11T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/profound-medical-to-present-first-captain-trial-results-comparing-tulsa-procedure-to-robotic-prostatectomy 2026-03-11T09:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profound-medical-to-present-first-captain-trial-results-comparing-tulsa-procedure-to-robotic-prostatectomy 2026-03-11T09:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/sanara-medtech-s-celleraterx-surgical-powder-shows-3852-cost-savings-per-patient-in-spine-surgery-study 2026-03-11T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanara-medtech-s-celleraterx-surgical-powder-shows-3852-cost-savings-per-patient-in-spine-surgery-study 2026-03-11T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/patrys-initiates-manufacturing-and-fda-engagement-for-injectable-delirium-treatment-rls-2201 2026-03-11T05:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patrys-initiates-manufacturing-and-fda-engagement-for-injectable-delirium-treatment-rls-2201 2026-03-11T05:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/acurastem-receives-target-als-grant-to-develop-syf2-targeted-therapeutics-for-tdp-43-dysfunction 2026-03-11T01:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acurastem-receives-target-als-grant-to-develop-syf2-targeted-therapeutics-for-tdp-43-dysfunction 2026-03-11T01:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeam-partners-with-mount-sinai-to-develop-ai-powered-home-cardiac-monitoring-platform 2026-03-11T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartbeam-partners-with-mount-sinai-to-develop-ai-powered-home-cardiac-monitoring-platform 2026-03-11T01:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/imagenebio-secures-30m-funding-to-advance-ox40-antagonist-img-007-through-phase-2-trials 2026-03-11T01:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagenebio-secures-30m-funding-to-advance-ox40-antagonist-img-007-through-phase-2-trials 2026-03-11T01:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/q32-bio-reports-positive-clinical-progress-for-bempikibart-in-alopecia-areata-with-36-week-data-expected-mid-2026 2026-03-11T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/q32-bio-reports-positive-clinical-progress-for-bempikibart-in-alopecia-areata-with-36-week-data-expected-mid-2026 2026-03-11T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/red-light-holland-acquires-filament-health-in-strategic-psychedelic-drug-development-merger 2026-03-11T01:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/red-light-holland-acquires-filament-health-in-strategic-psychedelic-drug-development-merger 2026-03-11T01:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/mindimmune-secures-5-million-addf-investment-to-advance-first-in-class-alzheimer-s-immunotherapy-miti-101 2026-03-11T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindimmune-secures-5-million-addf-investment-to-advance-first-in-class-alzheimer-s-immunotherapy-miti-101 2026-03-11T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/ems-acquires-sanofi-s-medley-for-500m-plans-semaglutide-generic-launch-in-brazil 2026-03-11T01:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ems-acquires-sanofi-s-medley-for-500m-plans-semaglutide-generic-launch-in-brazil 2026-03-11T01:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-cbd-pilot-program-sparks-debate-over-fda-standards-for-cannabinoid-reimbursement 2026-03-11T01:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-cbd-pilot-program-sparks-debate-over-fda-standards-for-cannabinoid-reimbursement 2026-03-11T01:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-identifies-statins-and-alpha-blockers-as-potential-life-extending-treatments-for-als-patients 2026-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-identifies-statins-and-alpha-blockers-as-potential-life-extending-treatments-for-als-patients 2026-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-acquires-majority-stake-in-cliniquantum-to-advance-quantum-powered-clinical-trials 2026-03-10T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurothera-labs-acquires-majority-stake-in-cliniquantum-to-advance-quantum-powered-clinical-trials 2026-03-10T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-photoswitch-therapy-shows-promise-for-advanced-retinitis-pigmentosa 2026-03-10T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-photoswitch-therapy-shows-promise-for-advanced-retinitis-pigmentosa 2026-03-10T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/cerevance-reports-positive-phase-2-results-for-novel-parkinson-s-drug-solengepras-targeting-motor-fluctuations-and-sleep-symptoms 2026-03-10T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerevance-reports-positive-phase-2-results-for-novel-parkinson-s-drug-solengepras-targeting-motor-fluctuations-and-sleep-symptoms 2026-03-10T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-secures-uspto-patent-for-tetravalent-bispecific-antibody-platform 2026-03-10T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alligator-bioscience-secures-uspto-patent-for-tetravalent-bispecific-antibody-platform 2026-03-10T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-advances-adc-pipeline-with-three-clinical-programs-set-for-2026-data-readouts 2026-03-10T17:12:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrogenics-advances-adc-pipeline-with-three-clinical-programs-set-for-2026-data-readouts 2026-03-10T17:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-s-troculeucel-shows-dose-dependent-cognitive-benefits-in-phase-1-alzheimer-s-disease-trials 2026-03-10T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkgen-biotech-s-troculeucel-shows-dose-dependent-cognitive-benefits-in-phase-1-alzheimer-s-disease-trials 2026-03-10T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/qlaris-bio-appoints-fred-guerard-as-ceo-as-qls-111-glaucoma-drug-enters-phase-3-development 2026-03-10T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlaris-bio-appoints-fred-guerard-as-ceo-as-qls-111-glaucoma-drug-enters-phase-3-development 2026-03-10T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-and-adiverna-partner-to-develop-world-s-first-ai-designed-mrna-vaccines-for-companion-animals 2026-03-10T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovaxys-and-adiverna-partner-to-develop-world-s-first-ai-designed-mrna-vaccines-for-companion-animals 2026-03-10T17:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/piston-bio-secures-fda-alignment-for-first-in-class-cancer-related-apathy-treatment-pst-101 2026-03-10T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piston-bio-secures-fda-alignment-for-first-in-class-cancer-related-apathy-treatment-pst-101 2026-03-10T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/aptorum-group-and-diamir-biosciences-publish-breakthrough-study-on-blood-based-glioblastoma-detection-using-microrna-biomarkers 2026-03-10T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptorum-group-and-diamir-biosciences-publish-breakthrough-study-on-blood-based-glioblastoma-detection-using-microrna-biomarkers 2026-03-10T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/ck-life-sciences-establishes-sequencio-therapeutics-to-advance-therapeutic-cancer-vaccine-portfolio 2026-03-10T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ck-life-sciences-establishes-sequencio-therapeutics-to-advance-therapeutic-cancer-vaccine-portfolio 2026-03-10T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/microbix-advances-manufacturing-modernization-for-kinlytic-urokinase-clot-dissolving-drug 2026-03-10T17:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbix-advances-manufacturing-modernization-for-kinlytic-urokinase-clot-dissolving-drug 2026-03-10T17:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/spark-biomedical-launches-phase-ii-luna-trial-testing-wearable-neurostimulation-for-heavy-menstrual-bleeding 2026-03-10T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spark-biomedical-launches-phase-ii-luna-trial-testing-wearable-neurostimulation-for-heavy-menstrual-bleeding 2026-03-10T17:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/foundation-medicine-expands-combomatch-participation-with-blood-based-biomarker-testing 2026-03-10T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foundation-medicine-expands-combomatch-participation-with-blood-based-biomarker-testing 2026-03-10T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/peptilogics-initiates-pivotal-trial-for-first-in-class-anti-biofilm-drug-plg0206-targeting-prosthetic-joint-infections 2026-03-10T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptilogics-initiates-pivotal-trial-for-first-in-class-anti-biofilm-drug-plg0206-targeting-prosthetic-joint-infections 2026-03-10T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-rare-cerebral-folate-transport-deficiency 2026-03-10T17:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-treatment-for-rare-cerebral-folate-transport-deficiency 2026-03-10T17:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/kcas-bio-lyon-site-achieves-level-a-glp-compliance-renewal-strengthening-ind-enabling-study-support 2026-03-10T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kcas-bio-lyon-site-achieves-level-a-glp-compliance-renewal-strengthening-ind-enabling-study-support 2026-03-10T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/etvax-oral-vaccine-shows-promise-against-deadly-e-coli-infections-in-children 2026-03-10T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/etvax-oral-vaccine-shows-promise-against-deadly-e-coli-infections-in-children 2026-03-10T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-expands-quviviq-access-to-gulf-states-through-pharmalink-partnership 2026-03-10T13:15:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idorsia-expands-quviviq-access-to-gulf-states-through-pharmalink-partnership 2026-03-10T13:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/c-further-launches-first-pediatric-cancer-programs-with-40m-budget-partners-with-mink-therapeutics 2026-03-10T13:15:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-further-launches-first-pediatric-cancer-programs-with-40m-budget-partners-with-mink-therapeutics 2026-03-10T13:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/daily-multivitamin-supplementation-slows-biological-aging-by-up-to-5-months-in-randomized-trial 2026-03-10T13:14:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daily-multivitamin-supplementation-slows-biological-aging-by-up-to-5-months-in-randomized-trial 2026-03-10T13:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/korro-bio-advances-rna-editing-platform-with-krro-121-nomination-and-85-million-financing 2026-03-10T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korro-bio-advances-rna-editing-platform-with-krro-121-nomination-and-85-million-financing 2026-03-10T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-nanopore-and-lonza-launch-first-gmp-grade-direct-rna-sequencing-solution-for-mrna-quality-control 2026-03-10T13:14:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-nanopore-and-lonza-launch-first-gmp-grade-direct-rna-sequencing-solution-for-mrna-quality-control 2026-03-10T13:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/lipum-secures-eur8-million-eu-grant-for-phase-2-rheumatoid-arthritis-trial-of-novel-bssl-targeting-antibody 2026-03-10T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipum-secures-eur8-million-eu-grant-for-phase-2-rheumatoid-arthritis-trial-of-novel-bssl-targeting-antibody 2026-03-10T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-face-platform-to-overcome-car-t-therapy-resistance-in-leukemia 2026-03-10T13:13:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-develop-face-platform-to-overcome-car-t-therapy-resistance-in-leukemia 2026-03-10T13:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/kainova-therapeutics-reports-positive-phase-i-results-for-oral-ep4-receptor-antagonist-dt-9081-in-advanced-solid-tumors 2026-03-10T13:13:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kainova-therapeutics-reports-positive-phase-i-results-for-oral-ep4-receptor-antagonist-dt-9081-in-advanced-solid-tumors 2026-03-10T13:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/nuformix-secures-fda-orphan-drug-designation-for-inhaled-ipf-therapy-nxp002 2026-03-10T13:12:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuformix-secures-fda-orphan-drug-designation-for-inhaled-ipf-therapy-nxp002 2026-03-10T13:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-co-founders-sahin-and-tureci-to-establish-new-mrna-company-by-2026 2026-03-10T13:12:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-co-founders-sahin-and-tureci-to-establish-new-mrna-company-by-2026 2026-03-10T13:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-eliminates-two-trial-requirement-for-drug-approvals-shifting-to-single-trial-default 2026-03-10T13:12:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-eliminates-two-trial-requirement-for-drug-approvals-shifting-to-single-trial-default 2026-03-10T13:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-compounds-show-promise-for-treating-liver-disease-affecting-one-third-of-adults 2026-03-10T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-compounds-show-promise-for-treating-liver-disease-affecting-one-third-of-adults 2026-03-10T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-restructures-operations-and-expands-biosimilar-pipeline-through-samsung-bioepis-partnership 2026-03-10T09:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-restructures-operations-and-expands-biosimilar-pipeline-through-samsung-bioepis-partnership 2026-03-10T09:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/ards-clinical-pipeline-expands-with-50-companies-developing-novel-therapies 2026-03-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ards-clinical-pipeline-expands-with-50-companies-developing-novel-therapies 2026-03-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-researchers-develop-next-generation-mrna-platform-to-overcome-efficacy-loss-in-elderly-and-obese-patients 2026-03-10T05:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaist-researchers-develop-next-generation-mrna-platform-to-overcome-efficacy-loss-in-elderly-and-obese-patients 2026-03-10T05:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/ibio-s-ibio-610-shows-fat-selective-weight-loss-in-non-human-primate-study 2026-03-10T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibio-s-ibio-610-shows-fat-selective-weight-loss-in-non-human-primate-study 2026-03-10T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/dobermann-trials-test-early-interventions-to-prevent-cardiogenic-shock-in-high-risk-ami-patients 2026-03-10T01:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dobermann-trials-test-early-interventions-to-prevent-cardiogenic-shock-in-high-risk-ami-patients 2026-03-10T01:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-ipos-grow-larger-in-q1-2026-despite-slow-pace-raising-1-7-billion 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-ipos-grow-larger-in-q1-2026-despite-slow-pace-raising-1-7-billion 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-expands-bucillamine-patent-portfolio-with-north-american-filings-for-chemical-warfare-agent-treatment 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revive-therapeutics-expands-bucillamine-patent-portfolio-with-north-american-filings-for-chemical-warfare-agent-treatment 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/intravascular-imaging-shows-sustained-clinical-benefits-at-5-years-in-complex-pci-procedures 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intravascular-imaging-shows-sustained-clinical-benefits-at-5-years-in-complex-pci-procedures 2026-03-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/care-ventures-group-invests-in-ren-health-to-build-ai-powered-women-s-wellness-platform 2026-03-09T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/care-ventures-group-invests-in-ren-health-to-build-ai-powered-women-s-wellness-platform 2026-03-09T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/csl-invests-1-5-billion-to-expand-illinois-plasma-therapy-manufacturing-with-advanced-horizon-2-technology 2026-03-09T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-invests-1-5-billion-to-expand-illinois-plasma-therapy-manufacturing-with-advanced-horizon-2-technology 2026-03-09T21:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-fda-510-k-clearance-for-cloud-native-diagnostic-viewer 2026-03-09T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-receives-fda-510-k-clearance-for-cloud-native-diagnostic-viewer 2026-03-09T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/brogidirsen-shows-sustained-motor-function-preservation-in-4-5-year-duchenne-muscular-dystrophy-trial 2026-03-09T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brogidirsen-shows-sustained-motor-function-preservation-in-4-5-year-duchenne-muscular-dystrophy-trial 2026-03-09T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-koselugo-for-adult-neurofibromatosis-type-1-patients-with-plexiform-neurofibromas 2026-03-09T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-koselugo-for-adult-neurofibromatosis-type-1-patients-with-plexiform-neurofibromas 2026-03-09T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/emalex-biosciences-initiates-expanded-access-program-for-novel-tourette-syndrome-therapy-ecopipam 2026-03-09T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emalex-biosciences-initiates-expanded-access-program-for-novel-tourette-syndrome-therapy-ecopipam 2026-03-09T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/verily-and-samsung-partner-to-integrate-galaxy-watch-8-data-into-clinical-research-platform 2026-03-09T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verily-and-samsung-partner-to-integrate-galaxy-watch-8-data-into-clinical-research-platform 2026-03-09T17:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/medidata-and-menarini-group-expand-ai-powered-partnership-to-accelerate-oncology-clinical-trials 2026-03-09T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medidata-and-menarini-group-expand-ai-powered-partnership-to-accelerate-oncology-clinical-trials 2026-03-09T17:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/crestone-s-crs3123-shows-superior-efficacy-in-phase-2-trial-for-c-difficile-infections 2026-03-09T17:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crestone-s-crs3123-shows-superior-efficacy-in-phase-2-trial-for-c-difficile-infections 2026-03-09T17:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-completes-fda-pre-license-inspection-for-biosimilars-manufacturing-with-minor-procedural-observations 2026-03-09T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-completes-fda-pre-license-inspection-for-biosimilars-manufacturing-with-minor-procedural-observations 2026-03-09T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/inhaled-crispr-cas9-nanoparticles-target-sting1-in-alveolar-macrophages-to-reverse-pulmonary-fibrosis-in-mice 2026-03-09T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhaled-crispr-cas9-nanoparticles-target-sting1-in-alveolar-macrophages-to-reverse-pulmonary-fibrosis-in-mice 2026-03-09T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/junshi-biosciences-achieves-regulatory-milestone-with-first-domestic-subcutaneous-anti-pd-1-antibody-application-in-china 2026-03-09T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/junshi-biosciences-achieves-regulatory-milestone-with-first-domestic-subcutaneous-anti-pd-1-antibody-application-in-china 2026-03-09T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/novelmed-s-ruxoprubart-achieves-100-transfusion-independence-in-pnh-phase-ii-trial-gains-regulatory-clearance-for-subcutaneous-dosing 2026-03-09T17:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novelmed-s-ruxoprubart-achieves-100-transfusion-independence-in-pnh-phase-ii-trial-gains-regulatory-clearance-for-subcutaneous-dosing 2026-03-09T17:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-and-genetix-extend-manufacturing-partnership-for-zynteglo-gene-therapy-amid-rising-patient-demand 2026-03-09T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-and-genetix-extend-manufacturing-partnership-for-zynteglo-gene-therapy-amid-rising-patient-demand 2026-03-09T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-dental-dedicated-mri-system-following-successful-clinical-trial 2026-03-09T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-dental-dedicated-mri-system-following-successful-clinical-trial 2026-03-09T17:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-secures-12-month-loan-extension-extends-cash-runway-to-q2-2027 2026-03-09T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tme-pharma-secures-12-month-loan-extension-extends-cash-runway-to-q2-2027 2026-03-09T13:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-acquires-biocare-medical-for-950-million-to-expand-cancer-diagnostics-portfolio 2026-03-09T13:11:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilent-acquires-biocare-medical-for-950-million-to-expand-cancer-diagnostics-portfolio 2026-03-09T13:11:20+00:00 hourly 0.9 https://trial.medpath.com/news/atamyo-therapeutics-reports-promising-early-results-for-ata-200-gene-therapy-in-rare-muscular-dystrophy 2026-03-09T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atamyo-therapeutics-reports-promising-early-results-for-ata-200-gene-therapy-in-rare-muscular-dystrophy 2026-03-09T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-completes-early-patient-enrollment-in-phase-3-trial-for-rare-neurodegenerative-disease-msa 2026-03-09T13:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-completes-early-patient-enrollment-in-phase-3-trial-for-rare-neurodegenerative-disease-msa 2026-03-09T13:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/bioduro-and-cenra-form-strategic-joint-venture-to-strengthen-global-api-manufacturing-network 2026-03-09T13:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioduro-and-cenra-form-strategic-joint-venture-to-strengthen-global-api-manufacturing-network 2026-03-09T13:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/kyron-bio-partners-with-servier-to-advance-precision-glycoengineering-for-next-generation-antibody-therapeutics 2026-03-09T13:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyron-bio-partners-with-servier-to-advance-precision-glycoengineering-for-next-generation-antibody-therapeutics 2026-03-09T13:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-and-kelun-biotech-receive-nmpa-approval-for-novel-bispecific-antibody-targeting-atopic-dermatitis 2026-03-09T13:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-and-kelun-biotech-receive-nmpa-approval-for-novel-bispecific-antibody-targeting-atopic-dermatitis 2026-03-09T13:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-secures-45-million-through-modified-licensing-agreement-with-healthcare-royalty-and-soleus-capital 2026-03-09T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-secures-45-million-through-modified-licensing-agreement-with-healthcare-royalty-and-soleus-capital 2026-03-09T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/t-knife-therapeutics-receives-european-authorization-for-first-in-human-trial-of-crispr-edited-t-cell-therapy-tk-6302 2026-03-09T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-knife-therapeutics-receives-european-authorization-for-first-in-human-trial-of-crispr-edited-t-cell-therapy-tk-6302 2026-03-09T09:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/lifevac-becomes-first-fda-authorized-suction-anti-choking-device-for-emergency-airway-clearance 2026-03-09T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifevac-becomes-first-fda-authorized-suction-anti-choking-device-for-emergency-airway-clearance 2026-03-09T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-announces-interim-results-from-phase-3-captivate-trial-of-claseprubart-for-cidp 2026-03-09T01:03:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-therapeutics-announces-interim-results-from-phase-3-captivate-trial-of-claseprubart-for-cidp 2026-03-09T01:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/nsw-government-expands-funding-for-cancer-clinical-trials-alliance-improving-patient-access-across-australia 2026-03-09T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsw-government-expands-funding-for-cancer-clinical-trials-alliance-improving-patient-access-across-australia 2026-03-09T01:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/claritas-neurocloudtm-receives-anvisa-approval-for-ai-powered-brain-imaging-analysis-in-brazil 2026-03-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/claritas-neurocloudtm-receives-anvisa-approval-for-ai-powered-brain-imaging-analysis-in-brazil 2026-03-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-acquires-full-control-of-u-s-r-d-unit-with-36-million-investment-to-advance-cancer-pipeline 2026-03-08T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-acquires-full-control-of-u-s-r-d-unit-with-36-million-investment-to-advance-cancer-pipeline 2026-03-08T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-completes-phase-3-trial-for-abp-206-opdivo-biosimilar-in-advanced-melanoma 2026-03-08T21:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-completes-phase-3-trial-for-abp-206-opdivo-biosimilar-in-advanced-melanoma 2026-03-08T21:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-advances-pipe-791-phase-2-trial-for-idiopathic-pulmonary-fibrosis-with-differentiated-lpa1-receptor-targeting 2026-03-08T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-therapeutics-advances-pipe-791-phase-2-trial-for-idiopathic-pulmonary-fibrosis-with-differentiated-lpa1-receptor-targeting 2026-03-08T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/self-amplifying-rna-therapy-shows-promise-for-heart-attack-recovery-in-preclinical-studies 2026-03-08T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/self-amplifying-rna-therapy-shows-promise-for-heart-attack-recovery-in-preclinical-studies 2026-03-08T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/cathworks-ffrangio-demonstrates-non-inferiority-to-invasive-pressure-wire-assessment-in-landmark-all-rise-trial 2026-03-08T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cathworks-ffrangio-demonstrates-non-inferiority-to-invasive-pressure-wire-assessment-in-landmark-all-rise-trial 2026-03-08T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/ataibeckley-explores-2-billion-deal-for-psychedelic-depression-drug-as-deutsche-bank-sees-major-market-potential 2026-03-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ataibeckley-explores-2-billion-deal-for-psychedelic-depression-drug-as-deutsche-bank-sees-major-market-potential 2026-03-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-oncology-companies-terminate-early-stage-solid-tumor-trials 2026-03-07T21:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-major-oncology-companies-terminate-early-stage-solid-tumor-trials 2026-03-07T21:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapeutic-strategies-target-chemoresistance-mechanisms-in-small-cell-lung-cancer 2026-03-07T21:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapeutic-strategies-target-chemoresistance-mechanisms-in-small-cell-lung-cancer 2026-03-07T21:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/ono-pharmaceutical-expands-ai-driven-drug-discovery-into-neurology-and-immunology-through-strategic-partnerships 2026-03-07T10:45:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ono-pharmaceutical-expands-ai-driven-drug-discovery-into-neurology-and-immunology-through-strategic-partnerships 2026-03-07T10:45:13+00:00 hourly 0.9 https://trial.medpath.com/news/amarin-faces-revenue-decline-as-vascepa-confronts-generic-competition-in-us-market 2026-03-07T10:45:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amarin-faces-revenue-decline-as-vascepa-confronts-generic-competition-in-us-market 2026-03-07T10:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-patient-with-advanced-nsclc-achieves-disease-stabilization-with-ivonescimab-in-china 2026-03-07T10:45:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-patient-with-advanced-nsclc-achieves-disease-stabilization-with-ivonescimab-in-china 2026-03-07T10:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-advances-novel-atac-technology-platform-with-multiple-cancer-candidates-in-clinical-development 2026-03-07T05:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-advances-novel-atac-technology-platform-with-multiple-cancer-candidates-in-clinical-development 2026-03-07T05:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/inmed-pharmaceuticals-winds-down-baymedica-operations-to-focus-on-cb1-cb2-receptor-drug-pipeline 2026-03-07T01:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmed-pharmaceuticals-winds-down-baymedica-operations-to-focus-on-cb1-cb2-receptor-drug-pipeline 2026-03-07T01:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-establishes-world-first-regulatory-framework-for-space-manufactured-medicines 2026-03-07T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-establishes-world-first-regulatory-framework-for-space-manufactured-medicines 2026-03-07T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/hamlet-biopharma-signs-letter-of-intent-for-alpha-1h-bladder-cancer-therapy-partnership 2026-03-07T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hamlet-biopharma-signs-letter-of-intent-for-alpha-1h-bladder-cancer-therapy-partnership 2026-03-07T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/d-d-pharmatech-and-first-bio-secure-european-patent-for-novel-brain-disease-drug-nly02 2026-03-07T01:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d-d-pharmatech-and-first-bio-secure-european-patent-for-novel-brain-disease-drug-nly02 2026-03-07T01:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/hypofractionated-radiotherapy-shows-promise-for-breast-cancer-treatment-with-reduced-treatment-time 2026-03-07T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypofractionated-radiotherapy-shows-promise-for-breast-cancer-treatment-with-reduced-treatment-time 2026-03-07T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/mindwalk-unveils-b-cell-llama-platform-for-next-generation-nanobody-discovery 2026-03-07T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindwalk-unveils-b-cell-llama-platform-for-next-generation-nanobody-discovery 2026-03-07T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lantheus-pylarify-truvu-for-enhanced-prostate-cancer-imaging 2026-03-07T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lantheus-pylarify-truvu-for-enhanced-prostate-cancer-imaging 2026-03-07T01:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/aisa-pharma-s-aisa-021-shows-promise-in-phase-2-trial-for-systemic-sclerosis-associated-raynaud-s-phenomenon 2026-03-06T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aisa-pharma-s-aisa-021-shows-promise-in-phase-2-trial-for-systemic-sclerosis-associated-raynaud-s-phenomenon 2026-03-06T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/ketone-body-b-hydroxybutyrate-enhances-car-t-cell-therapy-efficacy-in-preclinical-studies-human-trials-underway 2026-03-06T21:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketone-body-b-hydroxybutyrate-enhances-car-t-cell-therapy-efficacy-in-preclinical-studies-human-trials-underway 2026-03-06T21:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-clinical-trials-systematically-underreport-thromboembolic-risks-researchers-warn 2026-03-06T21:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-clinical-trials-systematically-underreport-thromboembolic-risks-researchers-warn 2026-03-06T21:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-pfizer-ceacam5-adc-trial-halted-in-europe-as-merck-kgaa-advances-competing-asset-to-phase-3 2026-03-06T21:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-pfizer-ceacam5-adc-trial-halted-in-europe-as-merck-kgaa-advances-competing-asset-to-phase-3 2026-03-06T21:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/stpharm-initiates-nipah-virus-mrna-vaccine-production-for-korean-pandemic-preparedness-initiative 2026-03-06T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stpharm-initiates-nipah-virus-mrna-vaccine-production-for-korean-pandemic-preparedness-initiative 2026-03-06T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/servier-acquires-day-one-biopharmaceuticals-for-2-5-billion-to-strengthen-rare-oncology-portfolio 2026-03-06T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-acquires-day-one-biopharmaceuticals-for-2-5-billion-to-strengthen-rare-oncology-portfolio 2026-03-06T17:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-receives-health-canada-approval-for-phase-ii-preeclampsia-trial-of-dm199 2026-03-06T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamedica-receives-health-canada-approval-for-phase-ii-preeclampsia-trial-of-dm199 2026-03-06T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/rowan-university-develops-first-robotic-system-for-minimally-invasive-long-bone-fracture-surgery 2026-03-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rowan-university-develops-first-robotic-system-for-minimally-invasive-long-bone-fracture-surgery 2026-03-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-first-eu-guidance-for-clinical-trials-during-public-health-emergencies 2026-03-06T17:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-first-eu-guidance-for-clinical-trials-during-public-health-emergencies 2026-03-06T17:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-executive-calls-for-fundamental-shift-in-clinical-trial-supply-models-amid-rising-market-pressures 2026-03-06T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-executive-calls-for-fundamental-shift-in-clinical-trial-supply-models-amid-rising-market-pressures 2026-03-06T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-launches-clinical-trials-for-xafty-world-s-first-oral-antiviral-drug-for-dengue-fever-treatment 2026-03-06T13:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-launches-clinical-trials-for-xafty-world-s-first-oral-antiviral-drug-for-dengue-fever-treatment 2026-03-06T13:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-patients-and-families-campaign-for-nhs-approval-of-zanidatamab-for-bile-duct-cancer 2026-03-06T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-patients-and-families-campaign-for-nhs-approval-of-zanidatamab-for-bile-duct-cancer 2026-03-06T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/exthera-medical-executive-pleads-guilty-to-concealing-patient-deaths-from-fda-in-blood-filtration-device-case 2026-03-06T05:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exthera-medical-executive-pleads-guilty-to-concealing-patient-deaths-from-fda-in-blood-filtration-device-case 2026-03-06T05:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/capitello-281-trial-shows-capivasertib-plus-abiraterone-maintains-quality-of-life-in-pten-deficient-prostate-cancer 2026-03-06T05:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capitello-281-trial-shows-capivasertib-plus-abiraterone-maintains-quality-of-life-in-pten-deficient-prostate-cancer 2026-03-06T05:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/cdt-equity-leverages-ai-platform-to-identify-rare-disease-drug-opportunities-across-multiple-therapeutic-areas 2026-03-06T01:15:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdt-equity-leverages-ai-platform-to-identify-rare-disease-drug-opportunities-across-multiple-therapeutic-areas 2026-03-06T01:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/hopewell-therapeutics-sublicenses-tissue-targeting-lipid-nanoparticles-to-foxcroft-for-novel-cancer-vaccine-development 2026-03-06T01:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hopewell-therapeutics-sublicenses-tissue-targeting-lipid-nanoparticles-to-foxcroft-for-novel-cancer-vaccine-development 2026-03-06T01:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-reports-positive-36-month-opregen-data-and-manufacturing-milestones-in-2025 2026-03-06T01:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lineage-cell-therapeutics-reports-positive-36-month-opregen-data-and-manufacturing-milestones-in-2025 2026-03-06T01:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-deepens-china-investment-with-eur170-million-manufacturing-expansion-and-drug-development-partnership 2026-03-06T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-deepens-china-investment-with-eur170-million-manufacturing-expansion-and-drug-development-partnership 2026-03-06T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/inimmune-appoints-new-chief-medical-officer-and-head-of-financial-strategy-ahead-of-phase-2-allergic-rhinitis-data 2026-03-06T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inimmune-appoints-new-chief-medical-officer-and-head-of-financial-strategy-ahead-of-phase-2-allergic-rhinitis-data 2026-03-06T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-launches-vantx-ai-platform-for-transplant-data-analytics-and-announces-170m-lab-products-divestiture 2026-03-06T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-launches-vantx-ai-platform-for-transplant-data-analytics-and-announces-170m-lab-products-divestiture 2026-03-06T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-advances-kras-g12d-inhibitor-to-phase-3-despite-fatal-pneumonitis-and-european-clinical-hold 2026-03-06T01:04:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-advances-kras-g12d-inhibitor-to-phase-3-despite-fatal-pneumonitis-and-european-clinical-hold 2026-03-06T01:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-remission-in-15-year-blood-cancer-patient-at-corewell-health 2026-03-06T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-achieves-remission-in-15-year-blood-cancer-patient-at-corewell-health 2026-03-06T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/bd-receives-ce-mark-approval-for-revello-vascular-covered-stent-to-treat-peripheral-artery-disease 2026-03-06T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-receives-ce-mark-approval-for-revello-vascular-covered-stent-to-treat-peripheral-artery-disease 2026-03-06T01:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/kestrel-therapeutics-receives-fda-clearance-for-pan-kras-inhibitor-kst-6051-phase-1-trial 2026-03-05T21:21:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kestrel-therapeutics-receives-fda-clearance-for-pan-kras-inhibitor-kst-6051-phase-1-trial 2026-03-05T21:21:54+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-therapeutics-direct-kras-inhibitors-show-promise-against-resistance-to-pan-ras-tri-complex-therapies 2026-03-05T21:21:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanta-therapeutics-direct-kras-inhibitors-show-promise-against-resistance-to-pan-ras-tri-complex-therapies 2026-03-05T21:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/medincell-raises-capital-to-advance-long-acting-injectable-platform-and-expand-partnerships 2026-03-05T21:16:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medincell-raises-capital-to-advance-long-acting-injectable-platform-and-expand-partnerships 2026-03-05T21:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/tangram-therapeutics-initiates-first-in-human-trial-of-tgm-312-for-mash-treatment 2026-03-05T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tangram-therapeutics-initiates-first-in-human-trial-of-tgm-312-for-mash-treatment 2026-03-05T21:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/fak-inhibition-unlocks-immune-response-against-treatment-resistant-ovarian-cancer 2026-03-05T21:14:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fak-inhibition-unlocks-immune-response-against-treatment-resistant-ovarian-cancer 2026-03-05T21:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cells-from-baby-teeth-show-promise-for-treating-cerebral-palsy-in-clinical-and-preclinical-studies 2026-03-05T21:14:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cells-from-baby-teeth-show-promise-for-treating-cerebral-palsy-in-clinical-and-preclinical-studies 2026-03-05T21:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-secures-105-million-series-c-to-advance-at-home-alzheimer-s-device-toward-2027-launch 2026-03-05T21:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognito-therapeutics-secures-105-million-series-c-to-advance-at-home-alzheimer-s-device-toward-2027-launch 2026-03-05T21:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/lifecore-biomedical-expands-partnership-with-indomo-to-advance-at-home-acne-treatment-device 2026-03-05T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifecore-biomedical-expands-partnership-with-indomo-to-advance-at-home-acne-treatment-device 2026-03-05T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-s-bxcl501-shows-promise-in-phase-2-trial-for-opioid-withdrawal-treatment 2026-03-05T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxcel-s-bxcl501-shows-promise-in-phase-2-trial-for-opioid-withdrawal-treatment 2026-03-05T17:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/liberate-bio-secures-myeloid-optimized-car-design-licenses-to-advance-in-vivo-car-m-programs 2026-03-05T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liberate-bio-secures-myeloid-optimized-car-design-licenses-to-advance-in-vivo-car-m-programs 2026-03-05T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/therna-partners-with-charles-river-to-develop-ai-designed-single-patient-rna-therapeutics-for-ultra-rare-diseases 2026-03-05T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therna-partners-with-charles-river-to-develop-ai-designed-single-patient-rna-therapeutics-for-ultra-rare-diseases 2026-03-05T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/immatics-advances-prame-cell-therapy-anzu-cel-toward-2027-market-launch-with-strong-phase-3-enrollment 2026-03-05T17:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immatics-advances-prame-cell-therapy-anzu-cel-toward-2027-market-launch-with-strong-phase-3-enrollment 2026-03-05T17:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/immunis-secures-exclusive-license-for-novel-parkinson-s-dyskinesia-treatment-kora 2026-03-05T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunis-secures-exclusive-license-for-novel-parkinson-s-dyskinesia-treatment-kora 2026-03-05T17:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-achieves-clinical-milestone-with-sirolimus-injection-for-rare-cancer-treatment 2026-03-05T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-achieves-clinical-milestone-with-sirolimus-injection-for-rare-cancer-treatment 2026-03-05T17:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-nclt-approval-for-subsidiary-merger-to-streamline-operations 2026-03-05T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-receives-nclt-approval-for-subsidiary-merger-to-streamline-operations 2026-03-05T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-bay-area-cryo-em-drug-discovery-center-to-accelerate-breakthrough-therapies 2026-03-05T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-opens-bay-area-cryo-em-drug-discovery-center-to-accelerate-breakthrough-therapies 2026-03-05T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-study-shows-neoadjuvant-therapy-nearly-doubles-disease-free-survival-in-intrahepatic-cholangiocarcinoma 2026-03-05T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-study-shows-neoadjuvant-therapy-nearly-doubles-disease-free-survival-in-intrahepatic-cholangiocarcinoma 2026-03-05T17:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/science-corp-raises-230m-series-c-to-advance-prima-brain-computer-interface-for-vision-restoration 2026-03-05T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/science-corp-raises-230m-series-c-to-advance-prima-brain-computer-interface-for-vision-restoration 2026-03-05T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/seqster-launches-1-click-datalake-platform-to-transform-clinical-trial-design-and-recruitment 2026-03-05T17:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seqster-launches-1-click-datalake-platform-to-transform-clinical-trial-design-and-recruitment 2026-03-05T17:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/early-automated-insulin-delivery-initiation-shows-superior-glycemic-control-in-youth-with-type-1-diabetes 2026-03-05T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-automated-insulin-delivery-initiation-shows-superior-glycemic-control-in-youth-with-type-1-diabetes 2026-03-05T13:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-cognita-s-ai-powered-chest-x-ray-interpretation-system 2026-03-05T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-cognita-s-ai-powered-chest-x-ray-interpretation-system 2026-03-05T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-proposes-public-funding-for-letermovir-to-prevent-life-threatening-cmv-infections-after-stem-cell-transplants 2026-03-05T05:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-proposes-public-funding-for-letermovir-to-prevent-life-threatening-cmv-infections-after-stem-cell-transplants 2026-03-05T05:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-single-dose-dengue-vaccine-shows-80-5-efficacy-against-hospitalization-in-five-year-phase-3-trial 2026-03-05T05:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-single-dose-dengue-vaccine-shows-80-5-efficacy-against-hospitalization-in-five-year-phase-3-trial 2026-03-05T05:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/gossamer-bio-s-seralutinib-fails-phase-3-prosera-trial-due-to-stringent-statistical-threshold 2026-03-05T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gossamer-bio-s-seralutinib-fails-phase-3-prosera-trial-due-to-stringent-statistical-threshold 2026-03-05T05:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/medidata-and-crio-partnership-delivers-near-perfect-data-accuracy-across-2500-global-clinical-trial-sites 2026-03-05T05:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medidata-and-crio-partnership-delivers-near-perfect-data-accuracy-across-2500-global-clinical-trial-sites 2026-03-05T05:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/cytisinicline-shows-promise-for-smoking-cessation-even-in-treatment-resistant-patients-phase-3-data-reveals 2026-03-05T01:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytisinicline-shows-promise-for-smoking-cessation-even-in-treatment-resistant-patients-phase-3-data-reveals 2026-03-05T01:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-advances-phase-2-parkinson-s-disease-trial-with-bezisterim-targeting-neuroinflammation-and-insulin-resistance 2026-03-05T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovie-advances-phase-2-parkinson-s-disease-trial-with-bezisterim-targeting-neuroinflammation-and-insulin-resistance 2026-03-05T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-zorevunersen-shows-up-to-91-seizure-reduction-in-children-with-dravet-syndrome 2026-03-05T01:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-zorevunersen-shows-up-to-91-seizure-reduction-in-children-with-dravet-syndrome 2026-03-05T01:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/cordenpharma-colorado-expands-peptide-development-capabilities-with-64000-square-foot-leed-gold-facility-at-flatiron-park 2026-03-04T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cordenpharma-colorado-expands-peptide-development-capabilities-with-64000-square-foot-leed-gold-facility-at-flatiron-park 2026-03-04T21:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/immunoscape-s-novel-seed-and-boost-platform-achieves-100-survival-in-ovarian-cancer-model-advances-to-clinical-trial 2026-03-04T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoscape-s-novel-seed-and-boost-platform-achieves-100-survival-in-ovarian-cancer-model-advances-to-clinical-trial 2026-03-04T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biological-launches-antigens-for-2026-2027-influenza-vaccine-strains-following-who-recommendations 2026-03-04T21:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biological-launches-antigens-for-2026-2027-influenza-vaccine-strains-following-who-recommendations 2026-03-04T21:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-pharma-strengthens-leadership-team-with-key-regulatory-and-patient-advocacy-appointments 2026-03-04T21:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nervgen-pharma-strengthens-leadership-team-with-key-regulatory-and-patient-advocacy-appointments 2026-03-04T21:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/cordis-launches-selution-slr-drug-eluting-balloon-in-japan-with-strong-three-year-clinical-data 2026-03-04T21:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cordis-launches-selution-slr-drug-eluting-balloon-in-japan-with-strong-three-year-clinical-data 2026-03-04T21:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/bryet-files-ind-application-for-ml-016-oncology-therapy-targeting-advanced-solid-tumors 2026-03-04T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bryet-files-ind-application-for-ml-016-oncology-therapy-targeting-advanced-solid-tumors 2026-03-04T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-novel-therapeutic-strategy-for-rett-syndrome-through-alternative-splicing-modulation 2026-03-04T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-novel-therapeutic-strategy-for-rett-syndrome-through-alternative-splicing-modulation 2026-03-04T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-launches-mako-rps-handheld-robotic-system-for-total-knee-replacement-surgery 2026-03-04T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-launches-mako-rps-handheld-robotic-system-for-total-knee-replacement-surgery 2026-03-04T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-expands-epetraborole-development-into-phase-2-trial-for-polycythemia-vera 2026-03-04T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-expands-epetraborole-development-into-phase-2-trial-for-polycythemia-vera 2026-03-04T17:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-successfully-transitions-live-phase-i-oncology-trial-from-manual-processes-to-automated-rtsm-system 2026-03-04T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-successfully-transitions-live-phase-i-oncology-trial-from-manual-processes-to-automated-rtsm-system 2026-03-04T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/alithea-genomics-secures-8-9m-to-scale-rna-sequencing-technology-for-drug-discovery 2026-03-04T17:29:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alithea-genomics-secures-8-9m-to-scale-rna-sequencing-technology-for-drug-discovery 2026-03-04T17:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/vericel-secures-fda-approval-for-advanced-cell-therapy-manufacturing-facility-to-expand-maci-production 2026-03-04T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vericel-secures-fda-approval-for-advanced-cell-therapy-manufacturing-facility-to-expand-maci-production 2026-03-04T17:27:42+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-and-akeso-partner-to-test-novel-dna-bispecific-antibody-combination-for-glioblastoma-treatment 2026-03-04T17:27:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-and-akeso-partner-to-test-novel-dna-bispecific-antibody-combination-for-glioblastoma-treatment 2026-03-04T17:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-ai-enabled-imaging-device-for-breast-cancer-surgery-margin-assessment 2026-03-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-ai-enabled-imaging-device-for-breast-cancer-surgery-margin-assessment 2026-03-04T17:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis-offering-hope-for-rare-voice-threatening-disease 2026-03-04T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis-offering-hope-for-rare-voice-threatening-disease 2026-03-04T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/novabridge-s-vis-101-shows-promising-phase-2a-results-in-wet-amd-with-potential-best-in-class-durability 2026-03-04T13:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novabridge-s-vis-101-shows-promising-phase-2a-results-in-wet-amd-with-potential-best-in-class-durability 2026-03-04T13:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-secures-1-1b-license-for-antengene-s-masked-t-cell-engager-atg-201-in-autoimmune-disease-push 2026-03-04T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-secures-1-1b-license-for-antengene-s-masked-t-cell-engager-atg-201-in-autoimmune-disease-push 2026-03-04T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/theolytics-secures-eur8-million-eu-grant-to-advance-novel-oncolytic-immunotherapy-for-platinum-resistant-ovarian-cancer 2026-03-04T13:04:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theolytics-secures-eur8-million-eu-grant-to-advance-novel-oncolytic-immunotherapy-for-platinum-resistant-ovarian-cancer 2026-03-04T13:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/roche-commits-520-million-investment-to-establish-south-korea-as-asian-clinical-trial-hub 2026-03-04T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-commits-520-million-investment-to-establish-south-korea-as-asian-clinical-trial-hub 2026-03-04T05:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/genevant-sciences-and-arbutus-biopharma-secure-2-25-billion-settlement-with-moderna-over-covid-19-vaccine-patent-infringement 2026-03-04T01:04:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genevant-sciences-and-arbutus-biopharma-secure-2-25-billion-settlement-with-moderna-over-covid-19-vaccine-patent-infringement 2026-03-04T01:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/teva-secures-400-million-from-blackstone-to-advance-tl1a-targeting-antibody-for-ibd-treatment 2026-03-04T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-secures-400-million-from-blackstone-to-advance-tl1a-targeting-antibody-for-ibd-treatment 2026-03-04T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-fluticasone-propionate-inhaler-with-180-day-market-exclusivity 2026-03-04T01:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-generic-fluticasone-propionate-inhaler-with-180-day-market-exclusivity 2026-03-04T01:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-de-novo-clearance-to-ai-powered-ultrasound-technology-for-predicting-delivery-dates 2026-03-04T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-de-novo-clearance-to-ai-powered-ultrasound-technology-for-predicting-delivery-dates 2026-03-04T01:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/cour-pharma-s-cnp-104-shows-sustained-liver-function-improvements-in-primary-biliary-cholangitis-one-year-study 2026-03-03T21:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cour-pharma-s-cnp-104-shows-sustained-liver-function-improvements-in-primary-biliary-cholangitis-one-year-study 2026-03-03T21:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-pbpk-modeling-to-replace-ten-clinical-trials-for-cml-drug-asciminib 2026-03-03T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-pbpk-modeling-to-replace-ten-clinical-trials-for-cml-drug-asciminib 2026-03-03T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/creatv-bio-s-lifetracdx-blood-test-supports-cytodyn-s-phase-2-colorectal-cancer-trial 2026-03-03T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creatv-bio-s-lifetracdx-blood-test-supports-cytodyn-s-phase-2-colorectal-cancer-trial 2026-03-03T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/sihuan-pharmaceutical-s-bireociclib-receives-nmpa-approval-for-first-line-hr-her2-advanced-breast-cancer-treatment 2026-03-03T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sihuan-pharmaceutical-s-bireociclib-receives-nmpa-approval-for-first-line-hr-her2-advanced-breast-cancer-treatment 2026-03-03T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/implanet-secures-fda-clearance-for-3d-printed-swingo-cervical-spine-cage 2026-03-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implanet-secures-fda-clearance-for-3d-printed-swingo-cervical-spine-cage 2026-03-03T21:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-and-liquid-ai-launch-lightweight-ai-model-for-on-premise-drug-discovery 2026-03-03T21:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-and-liquid-ai-launch-lightweight-ai-model-for-on-premise-drug-discovery 2026-03-03T21:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/yank-technologies-secures-2m-u-s-army-contract-for-wireless-charging-technology-development 2026-03-03T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yank-technologies-secures-2m-u-s-army-contract-for-wireless-charging-technology-development 2026-03-03T21:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/reprocell-launches-fda-compliant-gmp-manufacturing-platform-for-clinical-ipscs 2026-03-03T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reprocell-launches-fda-compliant-gmp-manufacturing-platform-for-clinical-ipscs 2026-03-03T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/isct-and-jsrm-launch-five-year-strategic-partnership-to-advance-ipsc-based-therapies-globally 2026-03-03T21:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isct-and-jsrm-launch-five-year-strategic-partnership-to-advance-ipsc-based-therapies-globally 2026-03-03T21:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-and-king-saud-university-launch-three-year-precision-medicine-initiative-for-familial-ibd 2026-03-03T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-and-king-saud-university-launch-three-year-precision-medicine-initiative-for-familial-ibd 2026-03-03T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/antiverse-raises-9-3m-series-a-to-develop-ai-designed-antibodies-for-challenging-disease-targets 2026-03-03T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antiverse-raises-9-3m-series-a-to-develop-ai-designed-antibodies-for-challenging-disease-targets 2026-03-03T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/cirrus-therapeutics-expands-to-singapore-unveils-novel-rpe-cell-therapy-for-geographic-atrophy 2026-03-03T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cirrus-therapeutics-expands-to-singapore-unveils-novel-rpe-cell-therapy-for-geographic-atrophy 2026-03-03T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-pharmacare-targets-canadian-market-entry-with-generic-ozempic-by-q3-2024 2026-03-03T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-pharmacare-targets-canadian-market-entry-with-generic-ozempic-by-q3-2024 2026-03-03T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/antiverse-secures-9-3m-series-a-to-advance-ai-powered-antibody-discovery-platform 2026-03-03T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antiverse-secures-9-3m-series-a-to-advance-ai-powered-antibody-discovery-platform 2026-03-03T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/quell-therapeutics-launches-phase-1-2-trial-of-novel-car-treg-therapy-for-autoimmune-diseases 2026-03-03T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quell-therapeutics-launches-phase-1-2-trial-of-novel-car-treg-therapy-for-autoimmune-diseases 2026-03-03T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/hepion-pharmaceuticals-in-licenses-novel-ctrna-biomarker-assay-for-early-hepatocellular-carcinoma-detection 2026-03-03T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepion-pharmaceuticals-in-licenses-novel-ctrna-biomarker-assay-for-early-hepatocellular-carcinoma-detection 2026-03-03T17:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/northsea-therapeutics-secures-orphan-drug-designations-for-orziloben-in-rare-liver-disease 2026-03-03T17:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northsea-therapeutics-secures-orphan-drug-designations-for-orziloben-in-rare-liver-disease 2026-03-03T17:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/adela-s-blood-based-test-shows-strong-predictive-power-for-immunotherapy-response-in-advanced-solid-tumors 2026-03-03T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adela-s-blood-based-test-shows-strong-predictive-power-for-immunotherapy-response-in-advanced-solid-tumors 2026-03-03T17:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/splisense-receives-ema-e-prime-designation-for-spl84-antisense-therapy-in-cystic-fibrosis 2026-03-03T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splisense-receives-ema-e-prime-designation-for-spl84-antisense-therapy-in-cystic-fibrosis 2026-03-03T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-juxtapid-for-pediatric-patients-with-homozygous-familial-hypercholesterolemia 2026-03-03T17:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-juxtapid-for-pediatric-patients-with-homozygous-familial-hypercholesterolemia 2026-03-03T17:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/syntis-bio-doses-first-patient-in-phase-1-1b-trial-of-novel-oral-obesity-treatment-synt-101 2026-03-03T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syntis-bio-doses-first-patient-in-phase-1-1b-trial-of-novel-oral-obesity-treatment-synt-101 2026-03-03T17:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/progeria-research-foundation-partners-with-forge-biologics-to-advance-crispr-gene-therapy-for-rare-aging-disease 2026-03-03T17:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/progeria-research-foundation-partners-with-forge-biologics-to-advance-crispr-gene-therapy-for-rare-aging-disease 2026-03-03T17:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/theravance-biopharma-s-phase-3-cypress-study-fails-primary-endpoint-company-winds-down-ampreloxetine-program 2026-03-03T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theravance-biopharma-s-phase-3-cypress-study-fails-primary-endpoint-company-winds-down-ampreloxetine-program 2026-03-03T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-harrow-s-phase-3-trial-for-triesence-in-cataract-surgery-patients 2026-03-03T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-harrow-s-phase-3-trial-for-triesence-in-cataract-surgery-patients 2026-03-03T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/growth-hormone-receptor-emerges-as-promising-target-for-therapy-resistant-lung-cancer 2026-03-03T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/growth-hormone-receptor-emerges-as-promising-target-for-therapy-resistant-lung-cancer 2026-03-03T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/sanaregen-vision-therapeutics-receives-fda-clearance-for-phase-i-ii-trial-of-cell-therapy-for-familial-drusen 2026-03-03T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanaregen-vision-therapeutics-receives-fda-clearance-for-phase-i-ii-trial-of-cell-therapy-for-familial-drusen 2026-03-03T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ataibeckley-advances-bpl-003-to-phase-3-trials-for-treatment-resistant-depression-following-fda-approval 2026-03-03T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ataibeckley-advances-bpl-003-to-phase-3-trials-for-treatment-resistant-depression-following-fda-approval 2026-03-03T13:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/secarna-pharmaceuticals-expands-ai-powered-oligonucleotide-partnership-with-curie-bio 2026-03-03T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secarna-pharmaceuticals-expands-ai-powered-oligonucleotide-partnership-with-curie-bio 2026-03-03T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/senhwa-biosciences-partners-with-ai-biotech-celltype-to-transform-cx-4945-into-next-generation-immunotherapy-platform 2026-03-03T13:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senhwa-biosciences-partners-with-ai-biotech-celltype-to-transform-cx-4945-into-next-generation-immunotherapy-platform 2026-03-03T13:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/hua-medicine-s-first-in-class-diabetes-drug-dorzagliatin-gains-hong-kong-approval-marking-international-expansion-milestone 2026-03-03T13:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hua-medicine-s-first-in-class-diabetes-drug-dorzagliatin-gains-hong-kong-approval-marking-international-expansion-milestone 2026-03-03T13:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/snipr-s-crispr-armed-phage-therapy-snipr001-demonstrates-safety-in-first-human-trial 2026-03-03T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/snipr-s-crispr-armed-phage-therapy-snipr001-demonstrates-safety-in-first-human-trial 2026-03-03T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/congruence-therapeutics-and-ono-pharmaceutical-expand-partnership-to-target-neurology-and-immunology-programs 2026-03-03T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congruence-therapeutics-and-ono-pharmaceutical-expand-partnership-to-target-neurology-and-immunology-programs 2026-03-03T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-cannabinoid-companies-achieve-european-cep-certification-for-pharmaceutical-grade-cbd 2026-03-02T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-major-cannabinoid-companies-achieve-european-cep-certification-for-pharmaceutical-grade-cbd 2026-03-02T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/argo-biopharma-strengthens-leadership-with-appointment-of-dr-gena-wang-as-cfo-and-chief-strategy-officer 2026-03-02T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argo-biopharma-strengthens-leadership-with-appointment-of-dr-gena-wang-as-cfo-and-chief-strategy-officer 2026-03-02T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-lithium-shows-promise-in-slowing-verbal-memory-decline-in-mild-cognitive-impairment 2026-03-02T21:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-lithium-shows-promise-in-slowing-verbal-memory-decline-in-mild-cognitive-impairment 2026-03-02T21:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/monopar-therapeutics-strengthens-leadership-team-ahead-of-alxn1840-nda-submission-for-wilson-disease 2026-03-02T21:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monopar-therapeutics-strengthens-leadership-team-ahead-of-alxn1840-nda-submission-for-wilson-disease 2026-03-02T21:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/imviva-s-allogeneic-car-t-therapy-cta313-achieves-100-response-rate-in-systemic-lupus-erythematosus-trial 2026-03-02T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imviva-s-allogeneic-car-t-therapy-cta313-achieves-100-response-rate-in-systemic-lupus-erythematosus-trial 2026-03-02T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-initiates-strategic-review-process-amid-major-restructuring-and-70-workforce-reduction 2026-03-02T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioatla-initiates-strategic-review-process-amid-major-restructuring-and-70-workforce-reduction 2026-03-02T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/xellsmart-secures-fourth-consecutive-fda-and-nmpa-approval-for-ipsc-cell-therapy-targeting-rare-neurodegenerative-disease-msa-p 2026-03-02T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xellsmart-secures-fourth-consecutive-fda-and-nmpa-approval-for-ipsc-cell-therapy-targeting-rare-neurodegenerative-disease-msa-p 2026-03-02T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/early-phase-clinical-trial-outsourcing-market-projected-to-reach-14-8-billion-by-2030-driven-by-personalized-medicine-growth 2026-03-02T17:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-phase-clinical-trial-outsourcing-market-projected-to-reach-14-8-billion-by-2030-driven-by-personalized-medicine-growth 2026-03-02T17:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/revir-therapeutics-initiates-phase-1-trial-of-rtx-117-for-rare-neurological-diseases 2026-03-02T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revir-therapeutics-initiates-phase-1-trial-of-rtx-117-for-rare-neurological-diseases 2026-03-02T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-acquires-cullgen-for-300m-to-expand-protein-degradation-platform 2026-03-02T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyre-therapeutics-acquires-cullgen-for-300m-to-expand-protein-degradation-platform 2026-03-02T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/rallybio-and-candid-therapeutics-announce-505-million-merger-to-advance-t-cell-engager-pipeline-for-autoimmune-diseases 2026-03-02T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rallybio-and-candid-therapeutics-announce-505-million-merger-to-advance-t-cell-engager-pipeline-for-autoimmune-diseases 2026-03-02T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/longbio-s-lp-003-demonstrates-superior-efficacy-over-xolair-in-phase-ii-chronic-urticaria-trial 2026-03-02T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longbio-s-lp-003-demonstrates-superior-efficacy-over-xolair-in-phase-ii-chronic-urticaria-trial 2026-03-02T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-skyrizi-demonstrates-superior-efficacy-in-phase-3-crohn-s-disease-trial-with-subcutaneous-induction 2026-03-02T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-skyrizi-demonstrates-superior-efficacy-in-phase-3-crohn-s-disease-trial-with-subcutaneous-induction 2026-03-02T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/pvp-labs-taphalgin-receives-dea-non-controlled-substance-designation-advancing-non-addictive-pain-management 2026-03-02T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pvp-labs-taphalgin-receives-dea-non-controlled-substance-designation-advancing-non-addictive-pain-management 2026-03-02T17:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/bd-receives-fda-clearance-for-first-1000ml-antimicrobial-irrigation-system-for-powered-surgical-lavage 2026-03-02T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-receives-fda-clearance-for-first-1000ml-antimicrobial-irrigation-system-for-powered-surgical-lavage 2026-03-02T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-receives-fda-tentative-approval-for-first-generic-version-of-lutathera-for-neuroendocrine-tumors 2026-03-02T17:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-receives-fda-tentative-approval-for-first-generic-version-of-lutathera-for-neuroendocrine-tumors 2026-03-02T17:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/talphera-reaches-50-enrollment-in-nafamostat-crrt-trial-targets-2026-fda-filing 2026-03-02T17:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talphera-reaches-50-enrollment-in-nafamostat-crrt-trial-targets-2026-fda-filing 2026-03-02T17:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/elutia-appoints-pete-ligotti-as-cco-to-lead-nxt-41x-commercial-launch-in-1-5b-breast-reconstruction-market 2026-03-02T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elutia-appoints-pete-ligotti-as-cco-to-lead-nxt-41x-commercial-launch-in-1-5b-breast-reconstruction-market 2026-03-02T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/avenacy-launches-generic-diphenhydramine-injectable-marking-26th-product-since-2023-inception 2026-03-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avenacy-launches-generic-diphenhydramine-injectable-marking-26th-product-since-2023-inception 2026-03-02T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/alaunos-therapeutics-reports-promising-preclinical-data-for-non-hormonal-obesity-drug-aln1003 2026-03-02T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alaunos-therapeutics-reports-promising-preclinical-data-for-non-hormonal-obesity-drug-aln1003 2026-03-02T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/turkish-universities-launch-clinical-trials-for-domestically-produced-car-t-cell-therapy-against-blood-cancers 2026-03-02T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turkish-universities-launch-clinical-trials-for-domestically-produced-car-t-cell-therapy-against-blood-cancers 2026-03-02T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/bimagrumab-semaglutide-combination-achieves-superior-weight-loss-with-preserved-muscle-mass-in-obesity-trial 2026-03-02T13:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimagrumab-semaglutide-combination-achieves-superior-weight-loss-with-preserved-muscle-mass-in-obesity-trial 2026-03-02T13:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-ralinepag-achieves-55-risk-reduction-in-pivotal-pah-trial-paving-way-for-fda-submission 2026-03-02T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-ralinepag-achieves-55-risk-reduction-in-pivotal-pah-trial-paving-way-for-fda-submission 2026-03-02T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/tolemy-bio-secures-eur1-4m-to-develop-ai-powered-cell-biology-platform-for-therapeutic-manufacturing 2026-03-02T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tolemy-bio-secures-eur1-4m-to-develop-ai-powered-cell-biology-platform-for-therapeutic-manufacturing 2026-03-02T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-s-paradise-ultrasound-renal-denervation-system-gains-insurance-coverage-in-japan-for-resistant-hypertension 2026-03-02T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-s-paradise-ultrasound-renal-denervation-system-gains-insurance-coverage-in-japan-for-resistant-hypertension 2026-03-02T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/jingfang-medicine-s-gfh375-receives-china-s-first-breakthrough-therapy-designation-for-kras-g12d-mutated-nsclc 2026-03-02T05:03:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jingfang-medicine-s-gfh375-receives-china-s-first-breakthrough-therapy-designation-for-kras-g12d-mutated-nsclc 2026-03-02T05:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/roquefort-therapeutics-acquires-tacc3-inhibitor-ao-252-in-ps31-9m-deal-rebrands-as-coiled-therapeutics 2026-03-02T05:03:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roquefort-therapeutics-acquires-tacc3-inhibitor-ao-252-in-ps31-9m-deal-rebrands-as-coiled-therapeutics 2026-03-02T05:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-epilepsy-drug-azetukalner-achieves-record-breaking-trial-results-paving-way-for-fda-approval 2026-03-02T01:03:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenon-pharmaceuticals-epilepsy-drug-azetukalner-achieves-record-breaking-trial-results-paving-way-for-fda-approval 2026-03-02T01:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-chicago-develops-targeted-mrna-nanoparticle-system-to-prevent-type-1-diabetes-progression 2026-03-01T21:03:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-chicago-develops-targeted-mrna-nanoparticle-system-to-prevent-type-1-diabetes-progression 2026-03-01T21:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/himalaya-trial-5-year-data-shows-durable-survival-benefit-for-stride-regimen-in-advanced-hepatocellular-carcinoma 2026-03-01T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/himalaya-trial-5-year-data-shows-durable-survival-benefit-for-stride-regimen-in-advanced-hepatocellular-carcinoma 2026-03-01T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-secures-new-funding-through-royalty-deal-as-dkn-01-advances-in-oncology-trials 2026-03-01T17:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-secures-new-funding-through-royalty-deal-as-dkn-01-advances-in-oncology-trials 2026-03-01T17:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/ssy-group-secures-first-in-china-approval-for-fat-soluble-vitamin-injection-expands-medical-device-portfolio 2026-03-01T17:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ssy-group-secures-first-in-china-approval-for-fat-soluble-vitamin-injection-expands-medical-device-portfolio 2026-03-01T17:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/caplin-steriles-secures-fda-approval-for-generic-desmopressin-injection-in-26-million-market 2026-03-01T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caplin-steriles-secures-fda-approval-for-generic-desmopressin-injection-in-26-million-market 2026-03-01T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/n4-pharma-pivots-to-rna-therapeutics-with-new-ceo-and-thalia-therapeutics-rebrand 2026-03-01T17:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n4-pharma-pivots-to-rna-therapeutics-with-new-ceo-and-thalia-therapeutics-rebrand 2026-03-01T17:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-cure-trial-shows-54-of-placebo-recipients-achieve-prolonged-viral-remission-after-receiving-experimental-therapy 2026-03-01T16:51:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-cure-trial-shows-54-of-placebo-recipients-achieve-prolonged-viral-remission-after-receiving-experimental-therapy 2026-03-01T16:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-receives-third-consecutive-fda-fee-waiver-for-cannabidiol-based-pain-treatment-in-dogs 2026-03-01T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocan-pharma-receives-third-consecutive-fda-fee-waiver-for-cannabidiol-based-pain-treatment-in-dogs 2026-03-01T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-reaches-clinical-milestone-as-first-patient-dosed-in-ideaya-s-b7h3-ptk7-bispecific-adc-phase-1-trial 2026-03-01T16:43:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocytogen-reaches-clinical-milestone-as-first-patient-dosed-in-ideaya-s-b7h3-ptk7-bispecific-adc-phase-1-trial 2026-03-01T16:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-biomarin-s-palynziq-for-adolescents-with-pku-expanding-treatment-access-to-ages-12-and-older 2026-03-01T16:42:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-biomarin-s-palynziq-for-adolescents-with-pku-expanding-treatment-access-to-ages-12-and-older 2026-03-01T16:42:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novo-nordisk-s-sogroya-for-three-additional-pediatric-growth-disorders 2026-02-28T01:01:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novo-nordisk-s-sogroya-for-three-additional-pediatric-growth-disorders 2026-02-28T01:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/one-third-of-rheumatologists-view-bristol-myers-squibb-s-sotyktu-as-substantial-advance-for-psoriatic-arthritis-ahead-of-march-6-fda-decision 2026-02-27T21:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-third-of-rheumatologists-view-bristol-myers-squibb-s-sotyktu-as-substantial-advance-for-psoriatic-arthritis-ahead-of-march-6-fda-decision 2026-02-27T21:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/gallant-partners-with-mwi-animal-health-to-establish-first-ultra-low-temperature-cold-chain-for-veterinary-stem-cell-therapy 2026-02-27T21:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gallant-partners-with-mwi-animal-health-to-establish-first-ultra-low-temperature-cold-chain-for-veterinary-stem-cell-therapy 2026-02-27T21:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/flare-therapeutics-reports-promising-phase-1a-results-for-first-in-class-pparg-inhibitor-fx-909-in-advanced-urothelial-cancer 2026-02-27T17:12:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flare-therapeutics-reports-promising-phase-1a-results-for-first-in-class-pparg-inhibitor-fx-909-in-advanced-urothelial-cancer 2026-02-27T17:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-to-present-phase-1-neo212-01-dose-escalation-results-for-cns-cancer-treatment 2026-02-27T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-to-present-phase-1-neo212-01-dose-escalation-results-for-cns-cancer-treatment 2026-02-27T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/blue-jet-healthcare-announces-2300-crore-pharmaceutical-manufacturing-facility-in-andhra-pradesh 2026-02-27T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blue-jet-healthcare-announces-2300-crore-pharmaceutical-manufacturing-facility-in-andhra-pradesh 2026-02-27T17:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-cevira-first-in-class-photodynamic-therapy-for-cervical-lesions 2026-02-27T17:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-accepts-marketing-authorization-application-for-cevira-first-in-class-photodynamic-therapy-for-cervical-lesions 2026-02-27T17:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-first-single-dose-oral-treatment-for-african-sleeping-sickness 2026-02-27T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-first-single-dose-oral-treatment-for-african-sleeping-sickness 2026-02-27T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-diverge-on-alzheimer-s-drug-approvals-as-italy-halts-reimbursement 2026-02-27T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-diverge-on-alzheimer-s-drug-approvals-as-italy-halts-reimbursement 2026-02-27T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-advances-modex-pipeline-with-five-clinical-programs-and-merck-ebv-vaccine-partnership 2026-02-27T06:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-advances-modex-pipeline-with-five-clinical-programs-and-merck-ebv-vaccine-partnership 2026-02-27T06:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/synthekine-partners-with-merck-to-evaluate-stk-012-combination-therapy-in-phase-2-nsclc-trial 2026-02-27T05:02:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthekine-partners-with-merck-to-evaluate-stk-012-combination-therapy-in-phase-2-nsclc-trial 2026-02-27T05:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/evox-therapeutics-partners-with-rett-syndrome-research-trust-to-advance-exoedit-gene-editing-platform-for-neurological-disease 2026-02-27T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evox-therapeutics-partners-with-rett-syndrome-research-trust-to-advance-exoedit-gene-editing-platform-for-neurological-disease 2026-02-27T01:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/arna-pharma-and-slate-run-pharmaceuticals-form-joint-venture-to-create-scaled-u-s-specialty-pharmaceutical-platform 2026-02-27T01:02:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arna-pharma-and-slate-run-pharmaceuticals-form-joint-venture-to-create-scaled-u-s-specialty-pharmaceutical-platform 2026-02-27T01:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-stem-cell-therapy-for-spina-bifida-shows-safety-in-groundbreaking-fetal-surgery-trial 2026-02-27T01:01:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-stem-cell-therapy-for-spina-bifida-shows-safety-in-groundbreaking-fetal-surgery-trial 2026-02-27T01:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-xofigo-plus-enzalutamide-reduces-death-risk-by-24-in-metastatic-prostate-cancer-trial 2026-02-26T21:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-xofigo-plus-enzalutamide-reduces-death-risk-by-24-in-metastatic-prostate-cancer-trial 2026-02-26T21:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-receives-second-positive-idmc-recommendation-for-phase-3-artemia-trial-of-tedopi-r-in-nsclc 2026-02-26T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-receives-second-positive-idmc-recommendation-for-phase-3-artemia-trial-of-tedopi-r-in-nsclc 2026-02-26T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-in-hampton-roads-receives-tricvalve-implant-in-fda-breakthrough-device-trial-for-severe-tricuspid-regurgitation 2026-02-26T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-in-hampton-roads-receives-tricvalve-implant-in-fda-breakthrough-device-trial-for-severe-tricuspid-regurgitation 2026-02-26T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/tecovirimat-fails-to-show-efficacy-against-mpox-in-landmark-stomp-trial 2026-02-26T21:02:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tecovirimat-fails-to-show-efficacy-against-mpox-in-landmark-stomp-trial 2026-02-26T21:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/ella-ai-health-advocate-receives-irb-exemption-advancing-ethical-clinical-trial-recruitment 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ella-ai-health-advocate-receives-irb-exemption-advancing-ethical-clinical-trial-recruitment 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/chop-and-penn-medicine-develop-first-crispr-platform-for-direct-analysis-of-patient-aml-cells 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chop-and-penn-medicine-develop-first-crispr-platform-for-direct-analysis-of-patient-aml-cells 2026-02-26T21:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/endra-s-taeus-liver-device-achieves-mri-level-consistency-in-masld-clinical-study 2026-02-26T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endra-s-taeus-liver-device-achieves-mri-level-consistency-in-masld-clinical-study 2026-02-26T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharma-s-rezatapopt-shows-promise-in-first-in-human-study-for-tp53-y220c-mutated-solid-tumors 2026-02-26T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharma-s-rezatapopt-shows-promise-in-first-in-human-study-for-tp53-y220c-mutated-solid-tumors 2026-02-26T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-acquires-sitryx-s-novel-oral-immunometabolic-program-in-500m-deal 2026-02-26T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-acquires-sitryx-s-novel-oral-immunometabolic-program-in-500m-deal 2026-02-26T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/kairos-pharma-signs-term-sheet-to-acquire-two-clinical-stage-lung-cancer-assets-from-celyn-therapeutics 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kairos-pharma-signs-term-sheet-to-acquire-two-clinical-stage-lung-cancer-assets-from-celyn-therapeutics 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/gemmabio-doses-first-patient-in-phase-1-2-trial-of-next-generation-gene-therapy-gb221-for-spinal-muscular-atrophy-type-1 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gemmabio-doses-first-patient-in-phase-1-2-trial-of-next-generation-gene-therapy-gb221-for-spinal-muscular-atrophy-type-1 2026-02-26T17:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-expands-manufacturing-partnership-with-ipsen-for-ultra-rare-fop-treatment 2026-02-26T17:02:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-sciences-expands-manufacturing-partnership-with-ipsen-for-ultra-rare-fop-treatment 2026-02-26T17:02:44+00:00 hourly 0.9 https://trial.medpath.com/news/asahi-kasei-acquires-german-antiviral-specialist-aicuris-for-eur780-million-to-expand-infectious-disease-portfolio 2026-02-26T17:02:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asahi-kasei-acquires-german-antiviral-specialist-aicuris-for-eur780-million-to-expand-infectious-disease-portfolio 2026-02-26T17:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/samchundang-secures-4-billion-european-glp-1-deal-with-breakthrough-patent-circumventing-technology 2026-02-26T13:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samchundang-secures-4-billion-european-glp-1-deal-with-breakthrough-patent-circumventing-technology 2026-02-26T13:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/hotspot-therapeutics-demonstrates-promising-preclinical-results-for-novel-irf5-inhibitors-in-autoimmune-disease-treatment 2026-02-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hotspot-therapeutics-demonstrates-promising-preclinical-results-for-novel-irf5-inhibitors-in-autoimmune-disease-treatment 2026-02-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/curanex-pharmaceuticals-completes-gmp-manufacturing-milestone-for-ulcerative-colitis-drug-candidate-phyto-n 2026-02-26T09:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curanex-pharmaceuticals-completes-gmp-manufacturing-milestone-for-ulcerative-colitis-drug-candidate-phyto-n 2026-02-26T09:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-technology-development-board-funds-indigenous-car-nk-cell-therapy-platform-for-cancer-and-leishmaniasis-treatment 2026-02-26T09:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-technology-development-board-funds-indigenous-car-nk-cell-therapy-platform-for-cancer-and-leishmaniasis-treatment 2026-02-26T09:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-linerixibat-receives-priority-review-in-china-for-rare-liver-disease-related-pruritus 2026-02-26T09:01:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-linerixibat-receives-priority-review-in-china-for-rare-liver-disease-related-pruritus 2026-02-26T09:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-s-tigris-trial-shows-significant-mortality-reduction-in-endotoxic-septic-shock-published-in-the-lancet 2026-02-26T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-medical-s-tigris-trial-shows-significant-mortality-reduction-in-endotoxic-septic-shock-published-in-the-lancet 2026-02-26T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/mahzi-therapeutics-doses-first-patient-in-groundbreaking-gene-therapy-trial-for-pitt-hopkins-syndrome 2026-02-26T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mahzi-therapeutics-doses-first-patient-in-groundbreaking-gene-therapy-trial-for-pitt-hopkins-syndrome 2026-02-26T05:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-surgical-acquires-j-j-s-neuwave-medical-to-expand-robotic-cancer-treatment-platform 2026-02-26T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-surgical-acquires-j-j-s-neuwave-medical-to-expand-robotic-cancer-treatment-platform 2026-02-26T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/b-c-teen-becomes-first-patient-cured-of-chronic-granulomatous-disease-using-prime-editing-gene-therapy 2026-02-26T05:01:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-c-teen-becomes-first-patient-cured-of-chronic-granulomatous-disease-using-prime-editing-gene-therapy 2026-02-26T05:01:44+00:00 hourly 0.9 https://trial.medpath.com/news/novel-p53-targeting-drug-rezatapopt-shows-20-response-rate-in-phase-1-trial-across-multiple-cancer-types 2026-02-26T01:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-p53-targeting-drug-rezatapopt-shows-20-response-rate-in-phase-1-trial-across-multiple-cancer-types 2026-02-26T01:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-numelvi-first-second-generation-jak-inhibitor-for-canine-allergic-dermatitis 2026-02-26T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-numelvi-first-second-generation-jak-inhibitor-for-canine-allergic-dermatitis 2026-02-26T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/optimi-health-launches-ibogaine-initiative-following-u-s-executive-order-on-psychedelic-drug-development 2026-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optimi-health-launches-ibogaine-initiative-following-u-s-executive-order-on-psychedelic-drug-development 2026-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/melodia-therapeutics-secures-key-u-s-patent-for-novel-dpp1-inhibitor-mld-151 2026-02-25T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/melodia-therapeutics-secures-key-u-s-patent-for-novel-dpp1-inhibitor-mld-151 2026-02-25T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/leveragen-secures-japanese-patent-for-singularity-platform-single-domain-antibody-discovery-technology 2026-02-25T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leveragen-secures-japanese-patent-for-singularity-platform-single-domain-antibody-discovery-technology 2026-02-25T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/nexus-precision-health-acquires-leal-health-to-scale-ai-powered-precision-medicine-platform 2026-02-25T21:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexus-precision-health-acquires-leal-health-to-scale-ai-powered-precision-medicine-platform 2026-02-25T21:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-oral-liquid-desmopressin-solution-for-central-diabetes-insipidus 2026-02-25T21:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-oral-liquid-desmopressin-solution-for-central-diabetes-insipidus 2026-02-25T21:02:00+00:00 hourly 0.9